

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/267733061>

Synthesis and Evaluation of Radioiodinated Acyloxymethyl Ketones as Activity-Based Probes for Cathepsin B

ARTICLE in JOURNAL OF MEDICINAL CHEMISTRY · OCTOBER 2014

Impact Factor: 5.45 · DOI: 10.1021/jm501357r · Source: PubMed

CITATIONS

2

READS

38

3 AUTHORS, INCLUDING:



Patricia Edem

McMaster University

3 PUBLICATIONS 2 CITATIONS

SEE PROFILE



Shannon Czorny

McMaster University

10 PUBLICATIONS 115 CITATIONS

SEE PROFILE

Synthesis and Evaluation of Radioiodinated Acyloxymethyl Ketones as Activity-Based Probes for Cathepsin B


Patricia E. Edem,[†] Shannon Czorny,[†] and John F. Valliant^{*,†,‡}

[†]Department of Chemistry & Chemical Biology, McMaster University, 1280 Main Street West, Hamilton, Ontario L8S 4M1, Canada

[‡]Centre for Probe Development and Commercialization, 1280 Main Street West, Hamilton, Ontario L8S 4K1, Canada

Supporting Information

ABSTRACT: Dipeptidyl (acyloxy)methyl ketones (AOMKs) were functionalized with different iodine-containing prosthetic groups to generate a library of candidate cathepsin B probes. Compound **23a**, (S)-20-[(S)-2-[(benzyloxy)carbonyl]-amino]-3-phenylpropanamido]-1-(4-iodophenyl)-1,14,21-trioxo-5,8,11-trioxa-2,15-diazadocosan-22-yl 2,4,6-trimethylbenzoate, was identified as a potential lead through in vitro screening, having a $K_i = 181 \pm 9$ nM and demonstrating the ability to effectively label active cathepsin B in vitro. Its less potent analogue **11a**, (S)-3-[(S)-2-[(benzyloxy)carbonyl]amino]-3-phenylpropanamido]-7-[6-(4-iodobenzamido)hexanamido]-2-oxoheptyl 2,4,6-trimethylbenzoate, was also tested as a comparison. Biodistribution studies of the iodine-125-labeled compounds in MDA-MB-231 mouse xenografts exhibited tumor uptake of $0.58\% \pm 0.06\%$ injected dose per gram (ID/g) for [¹²⁵I]**11a** and $1.12\% \pm 0.08\%$ ID/g for [¹²⁵I]**23a** at 30 min. The tumor-to-blood ratios reached 1.2 for [¹²⁵I]**23a** and 1.6 for [¹²⁵I]**11a** after 23 h. The more hydrophilic [¹²⁵I]**23a** showed an improved clearance profile with a superior tumor-to-muscle ratio of 7.0 compared to 3.4 for [¹²⁵I]**11a** at 23 h. Iodinated AOMK ligands are suitable in vitro probes for cathepsin B and hold promise as a platform to develop molecular imaging probes.



INTRODUCTION

Cathepsin B is a ubiquitously expressed lysosomal cysteine protease that is involved in normal physiological processes such as protein turnover, wound healing, and cell differentiation and growth.¹ The enzyme is overexpressed in a variety of cancers including breast carcinoma, prostate carcinoma, glioblastoma, and melanoma,^{2–5} with higher levels of active cathepsin B residing in tumors having high metastatic potential.^{6–8} In normal cells cathepsin B is localized in the lysosomes, yet in tumors it distributes throughout the cytoplasm and cell periphery and is secreted into the extracellular matrix as well.^{9–11} These features make cathepsin B an attractive target for developing molecular imaging probes for detecting cancer and assessing metastatic potential.

A number of near-infrared fluorescent (NIRF) probes for cathepsin B have been developed.^{12–15} Substrate-based probes such as Cat B 750 FAST and Cat B 680 FAST are commercially available and have been used in a number of cancer models.^{13,16–19} Most recently, substrate-based probes incorporating a self-immolative spacer linked to a fluorophore have been developed and used for in vitro and in vivo imaging of cathepsin B.^{12,20,21} Irreversible inhibitors have also been employed to develop activity-based probes (ABPs) for cathepsin B imaging.^{14,15,22–25}

ABPs for cathepsin B have been prepared from a number of different constructs including dipeptidyl (acyloxy)methyl ketones (AOMKs). The AOMK derivatives are attractive because of their specificity and high affinity for cysteine proteases in vitro and in vivo.^{26–29} These inhibitors inactivate

the enzyme by reacting with the active-site cysteine, resulting in a thioether linkage between the ABP and cathepsin B.^{1,27,30,31} Phe-Lys-AOMKs have been fluorescently labeled at the lysine ϵ -amine and have shown specific tumor uptake in vivo.^{14,15} Radiolabeled variants have also been developed where ⁶⁴Cu and the macrocyclic ligand 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was also incorporated at the P1 site.^{14,32} This construct exhibited a tumor uptake of $0.35\% \pm 0.13\%$ injected dose per gram (ID/g) at 30 min postinjection (pi) and the activity remained in the tumor at 24 h pi ($0.27\% \pm 0.05\%$ ID/g). High liver and kidney uptake was also observed, which is likely associated with loss of copper in vivo.³³

The present study describes the preparation and in vivo evaluation of novel dipeptidyl AOMK cathepsin B inhibitors bearing different iodine-containing prosthetic groups linked to the lysine ϵ -amine of a Phe-Lys-AOMK derivative. One of the advantages of working with iodine is that a single construct can be used to prepare agents for single photon emission tomography (SPECT), positron emission tomography (PET), or radiotherapy, simply by varying the isotope used (e.g., ¹²³I, ¹²⁴I, or ¹³¹I). This is exemplified by the use of aryl iodides to synthesize diagnostic and therapeutic radiopharmaceuticals for melanoma, glioma, and prostate cancer.^{34–38} Radioiodinated AOMKs have been used as ABPs to label diverse families of cysteine proteases in vitro but not cathepsin B, and they employed prosthetic groups that are not stable in vivo.²⁹ To

Received: August 20, 2014

Published: October 31, 2014




Figure 1. Structures of AOMK cathepsin B inhibitors. (a) Structures of parent AOMKs (**6a/b**) and initial iodinated AOMKs: iodobenzamides (**7a/b**) and iodophenylureas (**8a/b**). (b) Structures of AOMKs with alkyl spacer: iodobenzamides (**11a/b**), iodophenylureas (**15a/b**), and iodotriazole (**21**). (c) Structures of AOMKs with PEG spacer: iodobenzamides (**23a/b**) and iodotriazole (**29**) and the known optical probe GB123 (**30**).

evaluate the potential utility of iodinated AOMKs as molecular imaging probes, a library of candidates derived from robust iodine synthons were prepared and screened as inhibitors of cathepsin B. Two compounds were subsequently radiolabeled and tested in vitro and in vivo.


RESULTS AND DISCUSSION

Synthesis of Parent Inhibitors 6a and 6b. The parent AOMK inhibitors **6a** and **6b** (Figure 1a) were prepared from the protected dipeptide Cbz-Phe-Lys(ϵ -Boc)-OH (**3**). Following modified published procedures, isobutyl chloroformate (IBCF) (Scheme S1, route A) or benzotriazole (Scheme S1, route B; see Supporting Information) was used to couple the protected phenylalanine and lysine amino acids, giving **3**.^{39–41} The dipeptide **3** was activated with IBCF and treated with ethereal diazomethane to generate the diazomethyl ketone **4**, which was then converted to **5a** or **5b**, following the method of Blum et al.¹⁴ The amount of potassium fluoride used in the final step was reduced to help minimize epimerization of the lysine residue, which was evident by both HPLC and ¹H NMR in most compounds.^{27,40,42} The *tert*-butoxycarbonyl (Boc) group was subsequently removed by use of trifluoroacetic acid (TFA), giving **6a** or **6b** as TFA salts.

Synthesis of Initial Iodinated AOMKs. The first series of iodinated inhibitors prepared involved linking aryl iodides to the free amine of **6a**, giving iodobenzamides (**7a/b**) and iodophenylureas (**8a/b**) (Figure 1a). Compound **6a** was


coupled to 3- or 4-iodobenzoic acid by use of IBCF in the presence of *N*-methylmorpholine (NMM) (Scheme 1). The

Scheme 1. Synthesis of 7a/b




desired products **7a** and **7b** were isolated following simple extraction in yields of 29% and 45%, respectively. To generate the ureas, **6a** was combined with 3- or 4-iodophenyl isocyanate in the presence of triethylamine, giving **8a** and **8b** in 9% and 14% yields, respectively, following silica gel chromatography (Scheme 2).


Scheme 2. Synthesis of 8a/b



It has been reported that inhibitors containing bulky amino acids at the P1 position exhibit reduced affinity for cathepsin B.⁴³ To minimize possible steric interactions, a six-carbon spacer was also used to incorporate the aryl iodides (Figure 1b). 6-Aminohexanoic acid was combined with the active esters **9a** and **9b**, giving the aryl iodide spacers **10a** and **10b** in 82% and 87% yields, respectively (Scheme 3). These were linked to


Scheme 3. Synthesis of **11a/b**

6a by use of benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) in the presence of triethylamine to generate compounds **11a** and **11b** in 45% and 30% yields, respectively. For the urea derivatives, it was necessary to use the protected methyl 6-aminohexanoate **12** and combine it with 3- or 4-iodophenyl isocyanate (Scheme 4). Following deprotection, **14a** and **14b** were coupled with **6a** by use of IBCF in the presence of NMM to give **15a** and **15b** in 35% and 30% yields, respectively.

Scheme 4. Synthesis of **15a/b**

We have shown that iodinated triazoles are more polar than iodobenzene-based derivatives, have minimal nonspecific binding in vivo, and can clear readily via renal excretion.⁴⁴ To prepare a triazole-derived synthon to derivatize **6a**, ethynyl tributyltin was used in a 1,3-dipolar cycloaddition with **17**, giving the triazole **18** (Scheme 5). ¹H and ¹³C NMR spectroscopy confirmed that a single isomer was obtained, which is consistent with the literature.⁴⁵ Iododestannylation was achieved by treating **18** with molecular iodine to give **19** in 69% yield.⁴⁵ Following hydrolysis, **20** was coupled to **6a** by use of PyBOP in the presence of triethylamine to generate **21** in 33% yield.

Inhibition of Cathepsin B by Iodinated AOMKs. The binding affinity of the iodinated AOMKs was determined by a kinetic assay similar to that reported by Krantz et al.,²⁷ employing Cbz-Arg-Arg-*p*-nitroanilide (Z-RR-pNA) as the substrate and human liver cathepsin B (Calbiochem). Optimal enzyme concentration range and linearity was determined by monitoring substrate hydrolysis over time in the presence of

Scheme 5. Synthesis of **21**

various amounts of enzyme (Figure S1A, Supporting Information). The rate of hydrolysis (v_0) was linear when the enzyme concentration $[E]$ was between 5 and 15 nM ($R^2 > 0.99$) (Figure S1B, Supporting Information). The reaction rate (v_0) was also monitored when varying the substrate concentration in order to determine the Michaelis–Menten constant (K_m) (Figure S2, Supporting Information). A value of $390 \pm 20 \mu\text{M}$ was found, which is lower than the previously reported value of $900 \pm 60 \mu\text{M}$.⁴⁶ The variance is likely due to differences in the amount of dithiothreitol (DTT) used to activate the enzyme and the incubation time for this activation, as well as the enzyme source, which can influence the observed K_m for this substrate.^{46,47}

Inhibition constants (K_i) were determined by monitoring the substrate hydrolysis over time in the presence of 0–1 μM inhibitor (Figure S3A, Supporting Information). The observed rate constant (k_{obs}) was determined and plotted against the inhibitor concentration (Figure S3B, Supporting Information). By use of nonlinear regression, K_i values were determined where possible. In cases where full inhibition was not observed, only the second-order rate constant (k_i/K_i) was determined (Table 1).

The known inhibitor **6a** was evaluated as reference point to compare all iodinated derivatives. The measured K_i value was

Table 1. Inhibitory Activities of Iodinated AOMK Derivatives^a


compd	K_i (nM)	k_i/K_i ($\text{s}^{-1}\cdot\text{M}^{-1}$)
6a	80 ± 10	$40\,000 \pm 3000$
6b	52 ± 6	$40\,000 \pm 6000$
7a	2000 ± 1000	810 ± 80
7b	nd ^b	630 ± 10
8a	nd	0.013 ± 0.002
8b	nd	0.0035 ± 0.0002
11a	nd	310 ± 20
11b	nd	280 ± 20
15a	ni ^c	ni
15b	ni	ni
21	1000 ± 50	4430 ± 70
23a	181 ± 9	$21\,100 \pm 300$
23b	370 ± 25	$12\,700 \pm 600$
29	350 ± 40	9900 ± 200
30	120 ± 20	$19\,000 \pm 2000$

^aInhibition constants were determined at 37 °C and pH 6.0 with human liver cathepsin B. ^bFull inhibition was not observed; therefore, the value was not determined. ^cNo inhibition observed.

80 ± 10 nM, which differed from the reported value ($K_i = 170 \pm 50$ nM), again likely due to difference in enzyme sources.²⁷ The simple aryl iodide derivatives (**7a/b** and **8a/b**) showed poor affinity for the protease, where a K_i value could be determined only for **7a** ($K_i = 2 \pm 1$ μ M) and the ureas (**8a/b**) exhibited no detectable inhibition. Incorporation of the alkyl spacer did not show an improvement for the iodophenylureas (**15a/b**) or the iodobenzamides (**11a/b**). These compounds formed heterogeneous solutions when added to the assay buffer, indicating poor solubility, which in turn made it difficult to obtain accurate measures of the binding constants. The iodotriazole derivative **21** had improved solubility and showed improved binding affinity ($K_i = 1 \pm 0.05$ μ M) but was over 10 times less potent than the parent compound and was therefore regarded as a poor candidate.


Synthesis of Iodinated AOMKs Containing a Hydrophilic Linker. A more hydrophilic linker was used in an attempt to improve the solubility of the inhibitors and enhance their binding affinities. This was achieved by replacing the six-carbon spacer with a three-unit poly(ethylene glycol) (PEG) linker (Figure 1c). By use of similar methods, **9a** and **9b** were coupled to the tri(ethylene glycol) bifunctional linker to give the iodobenzamide-PEG derivatives **22a** and **22b** (Scheme 6). Compound **6a** was coupled to the new linkers by use of PyBOP in the presence of triethylamine, giving **23a** and **23b** in 22% and 37% yields, respectively.

Scheme 6. Synthesis of **23a/b**



To prepare the bifunctional triazole linker, triethylene glycol was combined with *tert*-butyl acrylate, generating the protected carboxylic acid **24** (Scheme 7). Compound **24** was converted to the mesylate and combined with sodium azide to generate **25**. Ethynyl tributyltin was used in a 1,3-dipolar cycloaddition with **25**, producing the triazole **26** as a single isomer. Treatment of **26** with iodine gave the iodinated triazole **27**, which was deprotected to generate **28**. The resultant iodotriazole PEG

Scheme 7. Synthesis of **29**




linker **28** was then coupled to **6a** by use of PyBOP in the presence of triethylamine, giving **29** in 37% yield.

Inhibition of Cathepsin B by Iodinated-PEG-AOMKs. Inhibitors containing the PEG spacer (**23a**, **23b**, and **29**) showed improved binding affinities over their alkyl counterparts (**11a**, **11b**, and **21**) with nanomolar K_i values (Table 1). The *p*-iodobenzamide **23a** exhibited the best affinity with a K_i of 181 ± 9 nM (Table 1). As an additional comparison, a known Cy5-labeled AOMK, GB123 (**30**, Figure 1c), was synthesized and tested. Reports of GB123 have shown good visualization of cathepsin B-positive tumors through optical imaging.^{14,48,49} A K_i value of 120 ± 20 nM was determined for **30**, suggesting that the K_i value for **23a** was sufficient to proceed to radiolabeling and biodistribution studies.

Synthesis of Radioiodinated AOMKs. To compare the effect of the hydrophilic spacer in vitro and in vivo, **11a** was selected alongside **23a** for radiolabeling and further testing. We have previously demonstrated that fluororous tin benzamides and phenylureas can be used to radioiodinate small molecules, and the products can be isolated without HPLC via a simple fluororous solid-phase extraction (FSPE).^{50,51} To convert the selected cathepsin B inhibitors to their radioactive analogues, the iodobenzamide precursors **10a** and **22a** were converted to the corresponding arylstannanes by use of fluororous distannane and a Pd-catalyzed cross-coupling reaction (Schemes S3 and S4, Supporting Information).⁵² Addition of the fluororous tin moiety was performed on the prosthetic group as opposed to the iodinated inhibitors to avoid degradation of the peptide backbone due to the harsh reaction conditions. The fluororous tin compounds **31** and **33** were coupled to **6a** by use of PyBOP in the presence of triethylamine, giving the precursors for radiolabeling **32** and **34** in 14% and 12% yields, respectively.

Radiolabeling was performed by treating **32** and **34** with [¹²⁵I]NaI in the presence of iodogen (Scheme 8). Following

Scheme 8. Synthesis of [¹²⁵I]**11a** and [¹²⁵I]**23a**



FSPE purification, isolated radiochemical yields were 32–36% ($n = 3$) for [¹²⁵I]**11a** and 26–35% ($n = 3$) for [¹²⁵I]**23a**. The modest radiochemical yields can be attributed to nonspecific binding of inhibitors to the reaction vessel and to the FSPE cartridge. The identities of the radiolabeled compounds were confirmed by coinjection with nonradioactive standards and correlation of retention times of peaks in the radiochromatograms and UV–visible chromatograms (Figures 2 and 3). Because of the long reaction times needed to couple the arylstannane spacers to **6a**, precursors **32** and **34** underwent some degree of epimerization. Consequently [¹²⁵I]**11a** and [¹²⁵I]**23a** also contained the associated epimers (~7% and 20%, respectively; Figures 2 and 3), similar to what has been observed for other AOMK derivatives.²⁸

Activity-Based Labeling of Cathepsin B. The affinity of the radiolabeled inhibitors for cathepsin B was evaluated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE). Equivalent amounts of cathepsin B were




Figure 2. HPLC chromatograms of [^{125}I]11a coinjected with the reference standard 11a. Radiochromatogram (upper trace) and UV–visible ($\lambda = 254 \text{ nm}$) chromatogram (lower trace) are shown.




Figure 3. Radiochromatogram (upper trace) and UV–visible ($\lambda = 254 \text{ nm}$) HPLC chromatogram (lower trace) of [^{125}I]23a coinjected with the reference standard 23a.

pretreated with saturating amounts of the known cathepsin B-specific inhibitor L-3-*trans*-(propylcarbonyl)oxirane-2-carbonyl-L-isoleucyl-L-proline (CA-074)⁵³ or with the vehicle (dimethyl sulfoxide, DMSO). The samples were then treated with [^{125}I] 11a or [^{125}I]23 and subjected to autoradiography. Despite different binding affinities, cathepsin B labeling was observed with both [^{125}I]11a and [^{125}I]23 (Figure 4). The activity in




Figure 4. Phosphor images of an SDS–polyacrylamide gel showing the specific labeling of active cathepsin B. Solutions of cathepsin B were pretreated with CA-074 (+) or DMSO (–), followed by (a) [^{125}I]11a or (b) [^{125}I]23a.

each band was blocked quantitatively by the addition of CA-074, indicating site-specific labeling of cathepsin B. It has been established that Phe-Lys-AOMKs can inactivate other cysteine cathepsins such as cathepsin L and cathepsin S.^{14,22,23,32} It is therefore expected that the iodine derivatives described here would show similar inhibition and selectivity.

Biodistributions of Activity-Based Probes in Tumor-Bearing Mice. The labeled probes, [^{125}I]11a and [^{125}I]23a, were administered intravenously into CD1 nu/nu mice bearing the MDA-MB-231 xenograft. MDA-MB-231 cells are known to express cathepsin B, and the xenografts have been used to evaluate other AOMK-based ABPs.^{14,54} After 0.5, 5, and 23 h pi, animals were sacrificed and the percent injected dose per

gram (ID/g) in various tissues, organs, and fluids was determined (Table 2).

After 30 min pi, bladder/urine ($90\% \pm 20\% \text{ ID/g}$), gall bladder ($170\% \pm 30\% \text{ ID/g}$), and liver ($16\% \pm 1\% \text{ ID/g}$) showed the highest uptake for [^{125}I]11a, which was reduced after 23 h pi ($0.9\% \pm 0.2\%$, $0.4\% \pm 0.1\%$, and $1.6\% \pm 0.2\% \text{ ID/g}$ respectively). Areas with the highest uptake at 23 h pi were thyroid/trachea ($17\% \pm 9\% \text{ ID/g}$), small intestine ($1.6\% \pm 0.2\% \text{ ID/g}$), and liver ($1.6\% \pm 0.2\% \text{ ID/g}$). The accumulation in thyroid/trachea is indicative of deiodination, as the sample did not contain any free iodide at the time of administration.⁵⁵ The initial tumor uptake was $0.58\% \pm 0.06\% \text{ ID/g}$ at 30 min pi and decreased over time. Despite this, the tumor/blood ratios increased from 0.5, reaching a maximum of 1.6 after 23 h pi (Figure 5a). Similarly the tumor/muscle ratios increased from 2.3, reaching a peak value of 4 at 5 h pi.

In the case of the more potent and hydrophilic derivative [^{125}I]23a, bladder/urine ($400\% \pm 200\% \text{ ID/g}$) and gall bladder ($42\% \pm 7\% \text{ ID/g}$) showed the highest uptake after 30 min pi. The liver uptake was lower in comparison to [^{125}I]11a ($3.4\% \pm 0.3\%$ vs $16\% \pm 1\% \text{ ID/g}$, 30 min pi), and the radioactivity was cleared from the majority of the tissues after 23 h pi. Again, accumulation in the thyroid/trachea was observed, indicating *in vivo* deiodination. The observed tumor uptake was higher for [^{125}I]23a ($1.12\% \pm 0.08\% \text{ ID/g}$) than that of [^{125}I]11a at 30 min, and the tumor/blood ratios showed an increase from 0.5 to 1.2 after 23 h pi (Figure 5b). In addition the tumor/muscle ratios increased from 2.1 to 7.3 for 23a, reaching a maximum at 23 h.

Compound [^{125}I]23a showed lower accumulation in non-target tissues in comparison with the previously reported ^{64}Cu AOMK derivative.³² When tested in MDA-MB-435 xenografts, it exhibited $<0.5\% \text{ ID/g}$ tumor uptake, a tumor-to-blood ratio of 0.61, and a tumor-to-muscle ratio of 3.03 at 2 h pi. Compound [^{125}I]23a exhibited similar tumor uptake at 5 h pi ($0.27\% \text{ ID/g}$) in the MDA-MB-231 xenografts, which have comparable levels of cathepsin B activity as the MDA-MB-435 model,¹⁴ while the tumor-to-blood (0.98) and tumor-to-muscle (5.31) ratios were higher for [^{125}I]23a.

CONCLUSION

This work explored the utility of the AOMK construct as a targeting vector to develop radioiodinated ABPs for cathepsin B. Attachment of bulky aromatic groups to the lysine side chain with and without an aliphatic spacer had a detrimental impact on cathepsin B binding when compared to the parent ligand. However, inhibitors containing a PEG spacer showed high affinity for the enzyme. Despite different binding affinities and lipophilicities, [^{125}I]11a and [^{125}I]23a were able to label cathepsin B *in vitro*, which was blocked in the presence of a known cathepsin B inhibitor. Evaluation of [^{125}I]23a in a human MDA-MB-231 breast cancer model showed improved tumor-to-nontumor ratios in comparison to other P1 radio-labeled AOMKs but modest total tumor uptake.

EXPERIMENTAL SECTION

Materials and Instrumentation. All chemicals, unless otherwise stated, were purchased from Sigma–Aldrich, Novabiochem, or Bachem and used without further purification. Cy5 succinimidyl ester was obtained from GE Healthcare. Tris(1*H*,1*H*,2*H*,2*H*-perfluorooctyl)tin hydride was obtained from Fluorous Technologies Inc. Diazomethane was prepared by use of the Diazald glassware set with system 45 connections (Aldrich) following the procedures

Table 2. Biodistribution of [^{125}I]11a and [^{125}I]23a in MDA-MB-231 Tumor-Bearing Mice^a

organ	[^{125}I]11a ^b (% ID/g)			[^{125}I]23a ^c (% ID/g)		
	30 min	5 h	23 h	30 min	5 h	23 h
blood	1.14 ± 0.09	0.43 ± 0.05	0.030 ± 0.003	2.3 ± 0.2	0.28 ± 0.03	0.04 ± 0.00
heart	0.68 ± 0.06	0.19 ± 0.02	0.030 ± 0.004	0.9 ± 0.2	0.11 ± 0.01	0.02 ± 0.00
lungs	2.2 ± 0.2	0.84 ± 0.09	0.21 ± 0.02	3.5 ± 0.5	0.59 ± 0.08	1 ± 1
liver	16 ± 1	4.5 ± 0.4	1.6 ± 0.2	3.4 ± 0.3	0.71 ± 0.07	0.29 ± 0.04
gall bladder	170 ± 30	60 ± 20	0.4 ± 0.1	42 ± 7	5 ± 1	0.17 ± 0.09
spleen	8 ± 2	1.3 ± 0.2	0.6 ± 0.1	1.5 ± 0.2	0.37 ± 0.04	0.13 ± 0.01
kidneys	2.9 ± 0.3	0.80 ± 0.05	0.20 ± 0.02	6 ± 1	0.55 ± 0.06	0.4 ± 0.1
stomach	3.8 ± 0.7	4.2 ± 0.6	0.15 ± 0.06	11 ± 3	2.2 ± 0.2	0.09 ± 0.01
small intestine	12 ± 1	10 ± 1	1.6 ± 0.2	5.9 ± 0.2	0.7 ± 0.2	0.07 ± 0.02
large intestine	0.30 ± 0.02	21 ± 2	0.63 ± 0.07	0.7 ± 0.1	4.9 ± 0.1	0.12 ± 0.02
tumor	0.58 ± 0.06	0.5 ± 0.1	0.040 ± 0.002	1.12 ± 0.08	0.27 ± 0.07	0.05 ± 0.01
thyroid/trachea	3.2 ± 0.8	19 ± 5	17 ± 9	11 ± 3	21 ± 9	20 ± 10
adipose	0.22 ± 0.05	0.100 ± 0.004	0.030 ± 0.005	1.1 ± 0.9	0.03 ± 0.01	0.01 ± 0.00
bone	0.52 ± 0.07	0.15 ± 0.01	0.030 ± 0.004	0.55 ± 0.07	0.09 ± 0.01	0.01 ± 0.00
skeletal muscle	0.25 ± 0.03	0.11 ± 0.02	0.010 ± 0.001	0.5 ± 0.2	0.05 ± 0.00	0.01 ± 0.00
brain	0.09 ± 0.01	0.04 ± 0.01	0.003 ± 0.001	0.19 ± 0.02	0.01 ± 0.00	0.00 ± 0.00
bladder and urine	90 ± 20	38 ± 9	0.9 ± 0.2	400 ± 200	31 ± 3	0.7 ± 0.2

^aValues are the mean % ID/g ± standard error from the mean. ^b_n = 5. ^c_n = 3.




Figure 5. Average tumor/blood and tumor/muscle ratios for (a) [^{125}I]11a ($n = 5$) and (b) [^{125}I]23a ($n = 3$).

provided by the supplier. As this is a toxic and explosive substance, the appropriate precautions should be exercised. 1,3,5,7-Tetramethyl-6-(2,4-dimethoxyphenyl)-2,4,8-trioxo-6-phosphadamantane was provided by the Capretta research group (McMaster University). [^{125}I]NaI (specific activity 629 GBq/mg) was provided by the McMaster nuclear reactor. As this is a radioactive isotope, appropriate facilities, licenses, and procedures should be in place prior to use.

For screening studies, human liver cathepsin B and Cbz-Arg-Arg-pNA were purchased from Calbiochem and Enzo Life Sciences, respectively. Reagents used in the assay buffer were from Sigma-Aldrich. Inhibitors were dissolved in biological-grade DMSO and diluted in the assay buffer. Black, clear-bottom 96-well plates were obtained from BD Biosciences. L-3-*trans*-(propylcarbonyl)oxirane-2-carbonyl-L-isoleucyl-L-proline (CA-074) was obtained from EMD Biosciences, precast gels were from Bio-Rad, and the gel drying kit was from Promega. 1,3,4,6-Tetrachloro-3a,6a-diphenylglycoluril (iodogen) was obtained from Thermo Scientific. According to HPLC analysis, supported by ^1H and ^{13}C NMR spectroscopy and high-resolution mass

spectrometry (HRMS), the chemical purity of all compounds screened for cathepsin B inhibition was >95%.

Microwave reactions were performed by use of a Biotage Initiator microwave synthesizer. Automated flash chromatography was performed on a Biotage SP1 flash purification system. Analytical thin-layer chromatography (TLC) was performed on silica gel plates with fluorescent indicator UV₂₅₄ (Macherey-Nagel) and visualized by use of UV light and ninhydrin or vanillin in EtOH. ^1H , ^{13}C , and two-dimensional NMR spectra were recorded on either a Bruker AV500 or AV600 spectrometer. ^1H NMR signals are reported in parts per million (ppm) measured relative to the residual proton signal of the deuterated solvent. Coupling constants (J) are reported in Hertz (Hz). ^{13}C signals are reported in ppm relative to the carbon signal from the solvent. HRMS was performed on a Waters/Micromass Q-ToF Ultima Global spectrometer. Analytical high-performance liquid chromatography (HPLC) was performed by use of an Agilent/Varian Pro Star model 330 photodiode array (PDA) detector, model 230 solvent delivery system, and Phenomenex Gemini (L × i.d. = 100 × 4.6 mm) column (5 μm C18). Semipreparative HPLC was performed by use of an Agilent/Varian Pro Star model 325 PDA detector, model 24 solvent delivery system, and Phenomenex Gemini (L × i.d. = 250 × 10 mm) column (5 μm C18). The elution conditions were as follows: (Method A) Solvent A = CH_3CN with 0.1% trifluoroacetic acid (TFA), solvent B = H_2O with 0.1% TFA. Gradient: 30% A to 100% A, 0–12 min; 100% A, 12–24 min; 100% A to 90% A, 24–28 min; 90% A to 30% A, 28–30 min. (Method B) Solvent A = CH_3CN , solvent B = H_2O . Gradient: 30% A to 100% A, 0–12 min; 100% A, 12–24 min; 100% A to 90% A, 24–28 min; 90% A to 30% A, 28–30 min. (Method C) Solvent A = CH_3CN , solvent B = H_2O . Gradient: 10% A, 0–2 min; 10% A to 90% A, 2–20 min; 90% A, 20–22 min; 90% A to 10% A, 22–23 min; 10% A, 23–25 min. The flow rate was set at 1 mL/min for analytical methods and 4 mL/min for semipreparative methods; monitoring occurred at 254 nm. Autoradiography was measured on a GE Storm 840 phosphor imager, and absorbance readings were performed on a Bio-Rad EL 808 plate reader. Radioactivity measurements for biodistribution and log P studies were made on a Wizard 1470 automated γ counter (PerkinElmer, Woodbridge, ON, Canada).

Synthetic Procedures for New Compounds. (S)-3-[(S)-2-[(Benzyloxy)carbonyl]amino]-3-phenylpropanamido]-7-(3-iodobenzamido)-2-oxoheptyl 2,4,6-Trimethylbenzoate (**7a**). To a solution of 4-iodobenzoic acid (72 mg, 290 μmol) in N,N -dimethylformamide (DMF) (12 mL) at -16°C , NMM (32 μL , 290 μmol) and IBCF (38 μL , 290 μmol) were added and left to stir until

dissolved. To this, **6a** (204 mg, 290 μ mol) was added, and the solution was left to stir overnight while warming to room temperature. The reaction mixture was diluted to 25 mL with water and extracted with EtOAc (3 \times 50 mL), and the combined organic layers were extracted with water (5 \times 20 mL), saturated Na₂CO₃ (3 \times 20 mL), water (20 mL), 5% (w/v) citric acid (3 \times 20 mL), water (20 mL), and brine (3 \times 20 mL) and then dried over MgSO₄. The solvent was removed by rotary evaporation and the product was isolated as a white powder. Yield 68 mg, 29%; mp 163–165 °C; TLC (2:1 EtOAc/Hex) *R*_f = 0.53; HPLC (method B) *t*_R = 18.1 min. ¹H NMR [600.13 MHz, (CD₃)₂SO] δ 8.51–8.48 (m, 2H, NHCHCONH and CH₂CH₂CH₂NH), 7.79 (d, *J* = 8.2 Hz, 2H, 2,6-C₆H₂H₂I), 7.63–7.60 (m, 1H, NHCHCOCH₂), 7.61 (d, *J* = 8.5 Hz, 2H, 3,5-C₆H₂H₂I), 7.33–7.18 (m, 10H, Ph), 6.91 (s, 2H, Me₃C₆H₂CO), 4.95 (s, 2H, PhCH₂OCO), 4.91 (d, *J* = 17.4 Hz, 1H, COCHHO), 4.82 (d, *J* = 17.2 Hz, 1H, COCHHO), 4.38–4.31 (m, 2H, HNCHCO Phe and Lys), 3.25–3.22 (m, 2H, CH₂CH₂CH₂NH), 3.01 (dd, *J* = 13.4, 5.0 Hz, 1H, CHCHHPh), 2.80 (dd, *J* = 13.1, 10.4 Hz, 1H, CHCHHPh), 2.26 [s, 6H, 2,6-(CH₃)₃C₆H₂CO], 2.25 [s, 3H, 4-(CH₃)₃C₆H₂CO], 1.84–1.82 (m, 1H, CHCHHCH₂CH₂), 1.62–1.56 (m, 1H, CHCHHCH₂CH₂), 1.55–1.47 (m, 2H, CH₂CH₂CH₂NH), 1.40–1.30 (m, 2H, CH₂CH₂CH₂NH). ¹³C NMR [150.92 MHz, (CD₃)₂SO] δ 202.7, 172.0, 168.2, 165.4, 155.8, 139.1, 137.8, 137.0, 136.9, 134.9, 134.1, 129.9, 129.2, 129.1, 128.3, 128.2, 128.1, 127.7, 127.5, 126.3, 98.5, 66.6, 65.3, 56.0, 55.9, 54.9, 37.3, 29.2, 28.6, 22.4, 20.7, 19.3. HRMS calcd for C₄₁H₄₅N₃O₇I [M + H]⁺, 818.2302; found, 818.2280.

(*S*)-3-[(*S*)-2-[(*Benzoyloxy*)carbonyl]amino]-3-phenylpropanamido]-7-[3-(4-iodobenzamido)-2-oxoheptyl]-2,4,6-Trimethylbenzoate (**7b**). To a solution of 3-iodobenzoic acid (72 mg, 290 μ mol) in DMF (12 mL) at –24 °C, NMM (33 μ L, 300 μ mol) and IBCF (39 μ L, 300 μ mol) were added and left to stir until dissolved. To this, **6a** (180 mg, 260 μ mol) was added and the solution was left to stir overnight while warming to room temperature. The reaction mixture was diluted to 25 mL with water and extracted with EtOAc (3 \times 20 mL), and the combined organic layers were extracted with water (5 \times 10 mL), saturated Na₂CO₃ (3 \times 10 mL), water (20 mL), 5% (w/v) citric acid (3 \times 10 mL), water (20 mL), and brine (3 \times 10 mL) and then dried over MgSO₄. Yield 95 mg, 45%; mp 135–140 °C; TLC (2:1 EtOAc/Hex) *R*_f = 0.83; HPLC (method B) *t*_R = 18.0 min. ¹H NMR [600.23 MHz, (CD₃)₂SO] δ 8.52 (m, 2H, NHCHCONH and CH₂CH₂CH₂NH), 8.18 (s, 1H, 2-C₆H₂H₂I), 7.86–7.83 (m, 2H, 4,6-C₆H₂H₂I), 7.63 (d, *J* = 8.2 Hz, 1H, NHCHCOCH₂), 7.33–7.18 (m, 10H, Ph), 6.91 (s, 2H, Me₃C₆H₂CO), 4.95 (s, 2H, PhCH₂OCO), 4.91 (d, *J* = 17.2 Hz, 1H, COCHHO), 4.81 (d, *J* = 17.2 Hz, 1H, COCHHO), 4.39–4.32 (m, 2H, HNCHCO Phe and Lys), 3.24 (m, 2H, CH₂CH₂CH₂NH), 3.02 (dd, *J* = 13.7, 5.3 Hz, 1H, CHCHHPh), 2.81 (dd, *J* = 13.5, 10.0 Hz, 1H, CHCHHPh), 2.26 (s, 6H, 2,6-(CH₃)₃C₆H₂CO), 2.25 (s, 3H, 4-(CH₃)₃C₆H₂CO), 1.87–1.78 (m, 1H, CHCHHCH₂CH₂), 1.64–1.56 (m, 1H, CHCHHCH₂CH₂), 1.56–1.47 (m, 2H, CH₂CH₂CH₂NH), 1.41–1.29 (m, 2H, CH₂CH₂CH₂NH). ¹³C NMR [150.92 MHz, (CD₃)₂SO] δ 202.6, 172.0, 168.2, 164.5, 155.8, 139.5, 139.1, 137.8, 136.9, 136.6, 135.6, 134.9, 130.4, 129.9, 129.2, 128.2, 128.1, 127.7, 127.5, 126.6, 126.3, 94.6, 66.6, 65.2, 56.0, 55.9, 40.0, 37.2, 29.1, 28.6, 22.5, 20.7, 19.3. HRMS calcd for C₄₁H₄₅N₃O₇I [M + H]⁺, 818.2302; found, 818.2291.

(*S*)-3-[(*S*)-2-[(*Benzoyloxy*)carbonyl]amino]-3-phenylpropanamido]-7-[3-(4-iodophenyl)ureido]-2-oxoheptyl-2,4,6-Trimethylbenzoate (**8a**). To a solution of 4-iodophenyl isocyanate (42 mg, 170 μ mol) in anhydrous CH₂Cl₂ (5 mL) were added Et₃N (24 μ L, 170 μ mol) and **6a** (119 mg, 170 μ mol), and the solution was left to stir for 3 h under a stream of Ar. The solvent was removed by rotary evaporation and the residue was dissolved in DMF (1 mL). This solution was then added dropwise to rapidly stirring cold water (approximately 100 mL), forming a white powder that was collected by centrifugation. The product was isolated as a white powder following flash chromatography (2:1 EtOAc/Hex). Yield 13 mg, 9%; mp 149–159 °C; TLC (2:1 EtOAc/Hex) *R*_f = 0.72; HPLC (method B) *t*_R = 17.3 min. ¹H NMR [600.13 MHz, (CD₃)₂SO] δ 8.55 (s, 1H, CONHC₆H₄I), 8.51 (d, *J* = 7.5 Hz, 1H, CONHCHCO), 7.63 (d, *J* =

8.3 Hz, 1H, CONHCHCO), 7.51–7.48 (m, 2H, CONHC₆H₂H₂I), 7.33–7.19 (m, 12H, ArH), 6.91 (s, 2H, Me₃C₆H₂CO), 6.20 (t, *J* = 5.4 Hz, 1H, CH₂CH₂CH₂NH), 4.96 (s, 2H, PhCH₂OCO), 4.91 (d, *J* = 17.2 Hz, 1H, COCH₂O), 4.81 (d, *J* = 17.2 Hz, 1H, COCHHO), 4.38–4.31 (m, 2H, HNCHCO Phe and Lys), 3.07–3.01 (m, 3H, CH₂CH₂CH₂NH, CHCHHPh), 2.81 (dd, *J* = 13.7, 9.8 Hz, 1H, CHCHHPh), 2.27 [s, 6H, 2,6-(CH₃)₃C₆H₂CO], 2.25 [s, 3H, 4-(CH₃)₃C₆H₂CO], 1.85–1.78 (m, 1H, CHCHHCH₂CH₂), 1.62–1.54 (m, 1H, CHCHHCH₂CH₂), 1.46–1.39 (m, 2H, CH₂CH₂CH₂NH), 1.39–1.33 (m, 1H, CHHCH₂CH₂NH), 1.32–1.25 (m, 1H, CHHCH₂CH₂NH). ¹³C NMR [150.92 MHz, (CD₃)₂SO] δ 202.7, 172.0, 168.2, 155.9, 154.9, 140.5, 139.1, 137.8, 137.1, 134.9, 129.9, 129.2, 128.3, 128.3, 128.2, 128.1, 127.7, 127.5, 126.3, 119.9, 83.3, 66.6, 65.3, 56.1, 55.9, 38.9, 37.2, 29.3, 29.2, 22.4, 20.7, 19.3. HRMS calcd for C₄₁H₄₆N₄O₇I [M + H]⁺, 833.2411; found, 833.2451.

(*S*)-3-[(*S*)-2-[(*Benzoyloxy*)carbonyl]amino]-3-phenylpropanamido]-7-[3-(4-iodophenyl)ureido]-2-oxoheptyl-2,4,6-Trimethylbenzoate (**8b**). Synthesized in a similar manner as **8a** with 3-iodophenyl isocyanate in place of 4-iodophenyl isocyanate. Yield 20 mg, 14%; mp 166–169 °C; TLC (2:1 EtOAc/Hex) *R*_f = 0.85; HPLC (method B) *t*_R = 18.0 min. ¹H NMR [600.13 MHz, (CD₃)₂SO] δ 8.60 (s, 1H, CONHC₆H₄I), 8.53 (d, *J* = 7.4 Hz, 1H, CONHCHCO), 7.96 (dd, *J* = 1.8, 1.8 Hz, 1H, 5-NHC₆H₂H₂I), 7.65 (d, *J* = 8.2 Hz, 1H, CONHCHCO), 7.34–7.20 (m, 12H, ArH), 6.99 (m, 1H, 2-NHC₆H₂H₂I), 6.92 (s, 2H, Me₃C₆H₂CO), 6.25 (t, *J* = 4.6 Hz, 1H, CH₂CH₂CH₂NH), 4.96 (s, 2H, PhCH₂OCO), 4.92 (d, *J* = 17.2 Hz, 1H, COCHHO), 4.81 (d, *J* = 17.2 Hz, 1H, COCHHO), 4.39–4.32 (m, 2H, HNCHCO Phe and Lys), 3.08–3.02 (m, 3H, CH₂CH₂CH₂NH and CHCH₂HPh), 2.82 (dd, *J* = 13.6, 9.8 Hz, 1H, CHCHHPh), 2.27 [s, 6H, 2,6-(CH₃)₃C₆H₂CO], 2.25 [s, 3H, 4-(CH₃)₃C₆H₂CO], 1.85–1.80 (m, 1H, CHCHHCH₂CH₂), 1.63–1.55 (m, 1H, CHCHHCH₂CH₂), 1.47–1.40 (m, 2H, CH₂CH₂CH₂NH), 1.39–1.33 (m, 1H, CHHCH₂CH₂NH), 1.32–1.27 (m, 1H, CHHCH₂CH₂NH). ¹³C NMR [150.92 MHz, (CD₃)₂SO] δ 202.7, 172.0, 168.2, 155.9, 154.9, 142.1, 139.1, 137.8, 134.9, 130.6, 129.3, 129.3, 129.2, 128.3, 128.2, 128.1, 127.7, 127.7, 127.5, 126.3, 125.6, 116.8, 94.7, 66.6, 65.3, 56.1, 55.9, 38.9, 37.2, 29.3, 29.2, 22.4, 20.7, 19.4. HRMS calcd for C₄₁H₄₆N₄O₇I [M + H]⁺, 833.2411; found, 833.2416.

(*S*)-3-[(*S*)-2-[(*Benzoyloxy*)carbonyl]amino]-3-phenylpropanamido]-7-[6-(4-iodobenzamido)hexanamido]-2-oxoheptyl-2,4,6-Trimethylbenzoate (**11a**). To a solution of **10a** (49 mg, 137 μ mol) in anhydrous DMF (2 mL), benzotriazol-1-yloxytriethylphosphonium hexafluorophosphate (PyBOP) (71 mg, 140 μ mol) was added and dissolved at 0 °C under a stream of Ar. Et₃N (38 μ L, 270 μ mol) was then added and allowed to stir for 5 min. Afterward **6a** (96 mg, 140 μ mol) and Et₃N (19 μ L, 140 μ mol) were added and the solution was stirred overnight at room temperature. The reaction mixture was diluted to 25 mL with water and extracted with CH₂Cl₂ (3 \times 15 mL), and the organic layers were combined and further extracted with water (5 \times 15 mL) and brine (30 mL) and then dried over Na₂SO₄. The solvent was removed by rotary evaporation, leaving an oily residue, which was then purified by flash chromatography (1–10% MeOH/CH₂Cl₂). The product was isolated as a white powder following lyophilization. Yield 57 mg, 45%; mp 190–196 °C; TLC (5% MeOH/CH₂Cl₂) *R*_f = 0.44; HPLC (method B) *t*_R = 17.3 min. ¹H NMR [600.13 MHz, (CD₃)₂SO] δ 8.48 (m, 2H, NHCHCONH and CH₂NHCOAr), 7.83 (d, *J* = 8.4 Hz, 2H, COC₆H₂H₂I), 7.71 (t, *J* = 5.7 Hz, 1H, CH₂NHCOCH₂), 7.63 (d, *J* = 8.4 Hz, 1H, NHCHCOCH₂), 7.61 (d, *J* = 8.4 Hz, 2H, COC₆H₂H₂I), 7.34–7.19 (m, 10H, Ph), 6.91 (s, 2H, Me₃C₆H₂CO), 4.97 (s, 2H, PhCH₂OCO), 4.91 (d, *J* = 17.2 Hz, 1H, COCHHO), 4.81 (d, *J* = 17.2 Hz, 1H, COCHHO), 4.36–4.32 (m, 2H, HNCHCO Phe and Lys), 3.23–3.19 (m, 2H, CH₂NHCOAr), 3.04–2.97 (m, 3H, CHCHHPh and CH₂NHCOCH₂), 2.84–2.79 (m, 1H, CHCHHPh), 2.27 [s, 6H, 2,6-(CH₃)₃C₆H₂CO], 2.25 [s, 3H, 4-(CH₃)₃C₆H₂CO], 2.04 (t, *J* = 7.5 Hz, 2H, CH₂NHCOCH₂), 1.82–1.76 (m, 1H, CHCHHCH₂CH₂), 1.60–1.54 (m, 1H, CHCHHCH₂CH₂), 1.49 (m, *J* = 7.4 Hz, 5H, CHCH₂CHHCH₂ and NHCOCH₂CH₂), 1.40–1.30 (m, 3H, CHCH₂CHHCH₂ and CH₂CH₂NHCO Lys), 1.28–1.22 (m, 2H, COCH₂CH₂CH₂). ¹³C

NMR [150.92 MHz, (CD₃)₂SO] δ 202.6, 172.0, 171.8, 168.2, 165.3, 155.8, 139.1, 137.8, 137.1, 136.9, 134.9, 134.1, 129.9, 129.2, 129.1, 128.3, 128.2, 128.1, 127.7, 127.5, 126.3, 98.5, 66.6, 65.3, 56.0, 55.9, 38.1, 38.1, 37.2, 35.4, 29.1, 28.8, 28.8, 26.2, 25.1, 22.4, 20.7, 19.3. HRMS calcd for C₄₇H₅₆N₄O₈I [M + H]⁺, 931.3143; found, 931.3104.

(S)-3-[(S)-2-[(Benzyloxy)carbonyl]amino]-3-phenylpropanamido]-7-[6-(3-iodobenzamido)hexanamido]-2-oxoheptyl 2,4,6-Trimethylbenzoate (**11b**). Synthesized in a similar manner as **11a** with **10a** in place of **10b**. Yield 38 mg, 30%; mp 159–162 °C; TLC (5% MeOH/CH₂Cl₂) R_f = 0.46; HPLC (method B) 'R = 17.4 min. ¹H NMR [600.13 MHz, (CD₃)₂SO] δ 8.54–8.51 (m, 2H, NHCHCONH and CH₂NHCOAr), 8.17 (s, 1H, NHCOC₆H₄I), 7.87 (d, J = 7.8 Hz, 1H, NHCOC₆H₄I), 7.83 (d, J = 7.9 Hz, 1H, NHCOC₆H₄I), 7.74 (t, J = 5.5 Hz, 1H, NHCHCOCH₂), 7.67 (d, J = 8.3 Hz, 1H, CH₂NHCOCH₂), 7.33–7.18 (m, 11H, Ph and NHCOC₆H₄I), 6.91 (s, 2H, Me₃C₆H₂CO), 4.96 (s, 2H, PhCH₂OCO), 4.90 (d, J = 17.3 Hz, 1H, COCHHO), 4.80 (d, J = 17.2 Hz, 1H, COCHHO), 4.35–4.31 (m, 2H, HNCHCO Phe and Lys), 3.22–3.19 (m, 2H, CH₂NHCOAr), 3.04–2.99 (m, 3H, CHCHHPh and CH₂NHCOCH₂), 2.80 (dd, J = 13.6, 9.8 Hz, 1H, CHCHHPh), 2.27 [s, 6H, 2,6-(CH₃)₃C₆H₂CO], 2.24 [s, 3H, 4-(CH₃)₃C₆H₂CO], 2.04 (t, J = 7.4 Hz, 2H, CH₂NHCOCH₂), 1.82–1.75 (m, 1H, CHCHHCH₂CH₂), 1.59–1.52 (m, 1H, CHCHHCH₂CH₂), 1.52–1.46 (m, 5H, CHCH₂CHHCH₂ and NHCOC₆H₄I), 1.39–1.30 (m, 3H, CHCH₂CHHCH₂ and CH₂CH₂NHCO Lys), 1.28–1.22 (m, 2H, COCH₂CH₂CH₂). ¹³C NMR [125.77 MHz, (CD₃)₂SO] δ 202.8, 172.15, 172.02, 168.4, 164.7, 156.0, 139.7, 139.3, 138.0, 137.1, 136.8, 135.7, 135.1, 130.6, 130.1, 129.4, 128.41, 128.39, 128.25, 127.86, 127.68, 126.8, 126.5, 94.8, 66.8, 65.5, 56.24, 56.09, 38.28, 38.25, 37.4, 35.5, 29.3, 28.9, 26.3, 25.2, 22.6, 20.8, 19.5, 19.1. HRMS calcd for C₄₇H₅₆N₄O₈I [M + H]⁺, 931.3143; found, 931.3161.

(S)-3-[(S)-2-(Benzyloxycarbonyl)-3-phenylpropanamido]-7-[6-(3-(4-iodophenyl)ureido)hexanamido]-2-oxoheptyl 2,4,6-Trimethylbenzoate (**15a**). To a solution of **14a** (56 mg, 150 μ mol) in anhydrous DMF (5 mL) were added NMM (17 μ L, 150 μ mol) and IBCF (21 μ L, 150 μ mol), and the mixture was stirred at –10 °C under a stream of Ar. After 1 min, **6a** (95 mg, 140 μ mol) and NMM (17 μ L, 150 μ mol) were added and the solution was left to stir overnight while warming to room temperature. The reaction mixture was diluted to 25 mL with water and extracted with EtOAc (3 \times 25 mL). The combined extracts were extracted with saturated Na₂CO₃ (3 \times 25 mL), water (25 mL), 5% (w/v) citric acid (3 \times 25 mL), and brine (3 \times 25 mL) and then dried over MgSO₄. The solvent was removed by rotary evaporation, leaving an oily residue, which was then purified by flash chromatography (1:1 EtOAc/Hex). The product was isolated as a white powder following lyophilization. Yield 45 mg, 35%; TLC (1:1 EtOAc/Hex) R_f = 0.60; HPLC (method B) 'R = 16.8 min. ¹H NMR [600 MHz, (CD₃)₂SO] δ 8.54–8.47 (m, 2H, NHCONHAr and NHCHCONH), 7.73–7.70 (m, 1H, CH₂NHCOCH₂), 7.65–7.61 (m, 1H, NHCHCOCH₂), 7.50 (d, J = 8.7 Hz, 1H, NHCOC₆H₄I), 7.34–7.18 (m, 12H, Ph and NHCOC₆H₄I), 6.91 (s, 2H, Me₃C₆H₂CO), 6.20–6.16 (m, 1H, NHCONHAr), 4.96 (s, 2H, PhCH₂OCO), 4.90 (d, J = 16.7 Hz, 1H, COCHHO), 4.80 (d, J = 17.4 Hz, 1H, COCHHO), 4.35–4.30 (m, 2H, HNCHCO Phe and Lys), 3.04–3.00 (m, 3H, CHCHHPh and CH₂NHCOCH₂), 2.99–2.93 (m, 1H), 2.83–2.80 (m, 1H, CHCHHPh), 2.27 [s, 6H, 2,6-(CH₃)₃C₆H₂CO], 2.25 [s, 3H, 4-(CH₃)₃C₆H₂CO], 2.04–2.02 (m, 2H, CH₂NHCOCH₂), 1.79–1.78 (m, 1H, CHCHHCH₂CH₂), 1.58–1.54 (m, 1H, CHCHHCH₂CH₂), 1.49–1.47 (m, 2H, NHCOC₆H₄I), 1.40–1.33 (m, 6H, CHCH₂CHHCH₂ and CH₂CH₂NHCO), 1.25–1.21 (m, 2H, COCH₂CH₂CH₂). ¹³C NMR [150.92 MHz, (CD₃)₂SO] δ 156.8, 154.9, 142.2, 137.1, 135.4, 134.9, 130.6, 129.3, 129.3, 128.3, 128.2, 128.1, 125.6, 119.8, 116.8, 109.1, 94.7, 65.3, 40.1, 33.99, 33.79, 29.5, 26.0, 24.3, 18.9. HRMS calcd for C₄₇H₅₇N₅O₈I [M + H]⁺, 946.3252; found, 946.3266.

(S)-3-[(S)-2-(Benzyloxycarbonyl)-3-phenylpropanamido]-7-[6-(3-(3-iodophenyl)ureido)hexanamido]-2-oxoheptyl 2,4,6-Trimethylbenzoate (**15b**). To a solution of **14b** (47 mg, 125 μ mol) in anhydrous DMF (5 mL) were added NMM (25 μ L, 250 μ mol) and IBCF (16 μ L, 125 μ mol), and the mixture was allowed to stir at –10

°C under a stream of Ar. After 1 min, **6a** (106 mg, 150 μ mol) and NMM (13 μ L, 125 μ mol) were added and the solution was left to stir overnight while warming to room temperature. The reaction mixture was made up to 25 mL with water and extracted with EtOAc (4 \times 25 mL). The combined extracts were extracted with saturated Na₂CO₃ (3 \times 25 mL), water (25 mL), 5% (w/v) citric acid (3 \times 25 mL), water (25 mL), and brine (3 \times 25 mL) and then dried over MgSO₄. The solvent was removed by rotary evaporation, leaving an oily residue, which was purified by flash chromatography (12–100% EtOAc/Hex). The product was isolated as a white powder following lyophilization. Yield 0.047 g, 30%; TLC (1:1 EtOAc/Hex) R_f = 0.60; HPLC (method B) 'R = 17.0 min. ¹H NMR [600 MHz, (CD₃)₂SO] δ 8.54 (s, 1H, NHCONHAr), 8.49 (d, J = 7.3 Hz, 1H, NHCHCONH), 7.96 (s, 1H, CONHC₆H₄I), 7.72–7.70 (m, 1H, CH₂NHCOCH₂), 7.64–7.62 (m, 1H, NHCHCOCH₂), 7.33–7.19 (m, 12H, Ph and NHCOC₆H₄I), 7.01–6.98 (m, 1H, NHCOC₆H₄I), 6.92 (s, 2H, Me₃C₆H₂CO), 6.20–6.17 (m, 1H, NHCONHAr), 4.97 (s, 2H, PhCH₂OCO), 4.91 (d, J = 17.2 Hz, 1H, COCHHO), 4.81 (d, J = 17.3 Hz, 1H, COCHHO), 4.36–4.31 (m, 2H, HNCHCO Phe and Lys), 3.07–3.01 (m, 6H, CH₂NHCONH, CHCHHPh, CH₂NHCOCH₂, and CHCHHCH₂CH₂), 2.83–2.79 (m, 1H, CHCHHPh), 2.28 [s, 6H, 2,6-(CH₃)₃C₆H₂CO], 2.25 [s, 3H, 4-(CH₃)₃C₆H₂CO], 2.21 (t, J = 7.4 Hz, 2H, CH₂NHCOCH₂), 2.06–2.03 (m, 1H, CHCHHCH₂CH₂), 1.52–1.49 (m, 1H, CHCHHCH₂CH₂), 1.43–1.37 (m, 6H, CHCH₂CHHCH₂ and CH₂CH₂NHCO), 1.31–1.25 (m, 2H, COCH₂CH₂CH₂). ¹³C NMR [151 MHz, (CD₃)₂SO] δ 174.8, 174.8, 142.5, 139.5, 138.2, 135.3, 133.5, 131.0, 129.7, 129.7, 128.7, 128.6, 128.5, 128.5, 128.1, 127.9, 126.0, 117.2, 95.1, 67.0, 65.7, 65.7, 56.3, 38.5, 37.7, 35.8, 34.1, 29.9, 29.8, 26.5, 26.3, 25.5, 24.7, 22.8, 20.1, 19.8. HRMS calcd for C₄₇H₅₇N₅O₈I [M + H]⁺, 946.3252; found, 946.3223.

Methyl 6-(4-(Tributylstannyl)-1H-1,2,3-triazol-1-yl)hexanoate (**18**). Tributyl(ethynyl)stannane (680 mg, 2.2 mmol) and **16** (310 mg, 1.8 mmol) were combined in toluene (2 mL) and heated to reflux at 120 °C for 14 h. The solvent was evaporated and the product was isolated as a colorless oil following flash chromatography (8–66% EtOAc/hexanes). Yield 680 mg, 78%; TLC (1:2 EtOAc/Hex) R_f = 0.55. ¹H NMR (600.13 MHz, CDCl₃) δ 7.41 (s, 1H, triazole-H), 4.36 (t, J = 7.2 Hz, 2H, NCH₂CH₂CH₂), 3.63 (s, 3H, CH₂CH₂COOCH₃), 2.28 (t, J = 7.4 Hz, 2H, CH₂CH₂CH₂COOMe), 1.93–1.88 (m, 2H, NCH₂CH₂CH₂CH₂), 1.67–1.60 (m, 2H, NCH₂CH₂CH₂CH₂), 1.59–1.47 [m, 6H, Sn(CH₂CH₂CH₂)₃], 1.37–1.27 [m, 8H, NCH₂CH₂CH₂ and Sn(CH₂CH₂CH₂)₃], 1.15–1.06 [m, 6H, Sn(CH₂CH₂CH₂)₃], 0.86 [t, J = 7.3 Hz, 9H, (CH₂CH₂CH₂CH₃)₃]. ¹³C NMR (150.92 MHz, CDCl₃) δ 173.8, 144.3, 129.7, 51.5, 49.3, 33.7, 30.2, 29.0, 27.2, 26.0, 24.3, 13.7, 9.9. HRMS calcd for C₂₁H₄₂N₃O₂Sn [M + H]⁺, 488.2303; found, 488.2280.

Methyl 6-(4-iodo-1H-1,2,3-triazol-1-yl)hexanoate (**19**). To a solution of **18** (490 g, 1.0 mmol) in tetrahydrofuran (THF, 8 mL) was added I₂ (280 g, 1.1 mmol), and the mixture was left to stir for 2 h. The solution was diluted to 25 mL with EtOAc, extracted with saturated Na₂S₂O₃ (3 \times 20 mL) and brine (20 mL), and dried over MgSO₄. The solvent was removed by rotary evaporation, and the product was isolated as a white solid following flash chromatography (8–66% EtOAc/hexanes). Yield 220 mg, 69%; mp 49–51 °C; TLC (1:2 EtOAc/Hex) R_f = 0.23. ¹H NMR (600.13 MHz, CDCl₃) δ 7.64 (s, 1H, triazole-H), 4.30 (t, J = 7.1 Hz, 2H, NCH₂CH₂CH₂), 3.55 (s, 3H, CH₂CH₂COOCH₃), 2.21 (t, J = 7.4 Hz, 2H, CH₂CH₂CH₂COOMe), 1.85–1.80 (m, 2H, NCH₂CH₂CH₂CH₂), 1.58–1.53 (m, 2H, NCH₂CH₂CH₂CH₂), 1.28–1.22 (m, 2H, NCH₂CH₂CH₂). ¹³C NMR (150.92 MHz, CDCl₃) δ 173.6, 129.1, 86.9, 51.5, 50.4, 33.6, 29.8, 25.8, 24.1. HRMS calcd for C₉H₁₅N₃O₂I [M + H]⁺, 324.0209; found, 324.0218.

6-(4-iodo-1H-1,2,3-triazol-1-yl)hexanoic acid (**20**). To **19** (190 mg, 600 μ mol) dissolved in CH₃CN (30 mL) was added 1 N NaOH (6 mL), and the solution was left to stir overnight. After the solvent was evaporated, the residue was dissolved in water (25 mL), and 1 N HCl (6 mL) was added. The product was then extracted with CH₂Cl₂ (3 \times 20 mL), and the combined organic layers were extracted with brine (20 mL) and dried over Na₂SO₄. The product was obtained as a white wax following rotary evaporation. Yield 150 g, 80%; mp 73–77

°C; TLC (5% MeOH/CH₂Cl₂) R_f = 0.52. ¹H NMR (600.13 MHz, CDCl₃) δ 7.62 (s, 1H, triazole-H), 4.40 (t, J = 7.1 Hz, 2H, NCH₂CH₂CH₂), 2.38 (t, J = 7.3 Hz, 2H, CH₂CH₂CH₂COOH), 1.97–1.92 (m, 2H, NCH₂CH₂CH₂CH₂), 1.72–1.67 (m, 2H, NCH₂CH₂CH₂CH₂), 1.42–1.37 (m, 2H, NCH₂CH₂CH₂). ¹³C NMR (150.92 MHz, CDCl₃) δ 178.5, 128.8, 86.9, 50.3, 33.4, 29.8, 25.7, 23.8. HRMS calcd for C₈H₁₃N₃O₂I [M + H]⁺, 310.0052; found, 310.0045.

(*S*)-3-[(*S*)-2-[(Benzyloxy)carbonyl]amino]-3-phenylpropanamido]-7-[6-(4-iodo-1*H*-1,2,3-triazol-1-yl)hexanamido]-2-oxoheptyl 2,4,6-Trimethylbenzoate (**21**). To a solution of **20** (42 mg 140 μ mol) in anhydrous DMF (10 mL), PyBOP (71 mg, 140 μ mol) was added and allowed to dissolve while the reaction mixture was kept at 0 °C under a stream of Ar. Et₃N (38 μ L, 270 μ mol) was added and the solution was left to stir for 5 min. Afterward, **6a** and Et₃N (19 μ L 140 μ mol) were added and the reaction mixture was allowed to warm to room temperature overnight with stirring. The solution was made up to 25 mL with water and extracted with CH₂Cl₂ (5 \times 15 mL), and the combined organic layers extracted with water (5 \times 15 mL) and brine (3 \times 25 mL). The solvent was evaporated and the product was obtained following flash chromatography (1–10% MeOH/CH₂Cl₂) as a white solid. Yield 40 mg, 33%; mp 102–109 °C; TLC (5% MeOH/CH₂Cl₂) R_f = 0.15. ¹H NMR [600.13 MHz, (CD₃)₂SO] δ 8.48 (d, J = 7.5 Hz, 1H, NHCHCONH), 8.33 (s, 1H, triazole-H), 7.71 (t, J = 5.5 Hz, 1H, CH₂NHCOCH₂), 7.62 (d, J = 8.3 Hz, 1H, NHCHCOCH₂), 7.33–7.18 (m, 10H, Ph) 6.91 (s, 2H, Me₃C₆H₂CO), 4.96 (s, 2H, PhCH₂OCO), 4.91 (d, J = 17.3 Hz, 1H, COCHHO), 4.80 (d, J = 17.3 Hz, 1H, COCHHO), 4.36–4.31 (m, 4H, CH₂N₃C₂HI and HNCHCO Phe and Lys), 3.04–2.99 (m, 4H CH₂NHCOCH₂ and CHCHHPh), 2.81 (dd, J = 13.8, 9.8 Hz, 1H, CHCHHPh), 2.26 [s, 6H 2,6-(CH₃)₂C₆H₃CO], 2.25 [s, 3H, 4-(CH₃)₃C₆H₂CO], 2.02 (t, J = 7.4 Hz, 2H, CH₂NHCOCH₂), 1.79–1.72 (m, 3H, CHCHHCH₂CH₂ and CH₂CH₂N₃C₂HI), 1.58–1.55 (m, 1H, CHCHHCH₂CH₂), 1.51–1.46 (m, 2H, NHCOCH₂CH₂), 1.40–1.23 (m, 4H CHCH₂CH₂CH₂), 1.18–1.12 (m, 2H, COCH₂CH₂CH₂). ¹³C NMR [150.91 MHz, (CD₃)₂SO] δ 202.6, 172.0, 171.7, 168.2, 155.9, 139.1, 137.8, 136.9, 136.1, 134.9, 129.9, 129.2, 128.26, 128.08, 127.69, 127.50, 126.3, 88.3. HRMS calcd for C₄₂H₅₂N₆O₇I [M + H]⁺, 879.2943; found, 879.2915.

1-(4-Iodophenyl)-1-oxo-5,8,11-trioxo-2-azatetradecan-14-oic Acid (**22a**). 3-{2-[2-(2-Aminoethoxy)ethoxy]ethoxy}propanoic acid (332 mg, 1.5 mmol) and **9a** (173 mg, 0.5 mmol) were added to DMF (2 mL) in a 2–5 mL microwave vial. The solution was heated in a microwave at 120 °C for 8 min. Afterward, water (5 mL) was added and the mixture was extracted with CH₂Cl₂ (3 \times 10 mL); the organic layers were combined and then extracted with water (5 \times 10 mL) and brine (3 \times 10 mL) and dried over Na₂SO₄. The product was isolated as a white solid following flash chromatography [1–10% MeOH/CH₂Cl₂ (with 0.1% AcOH)]. Yield 150 mg, 67%; mp 56–64 °C; TLC [5% MeOH/CH₂Cl₂ (with AcOH)] R_f = 0.25. ¹H NMR (600.13 MHz, CDCl₃) δ 7.77 (d, J = 8.3 Hz, 2H, NHCOC₆H₄H₂I), 7.56 (d, J = 8.4 Hz, 2H, NHCOC₆H₄H₂I), 7.04 (br s, NHCH₂CH₂O), 3.74 (t, J = 6.0 Hz, 2H, NHCH₂CH₂O), 3.69–3.63 [m, 12H, (CH₂OCH₂)₃], 2.59 (t, J = 5.7 Hz, 2H, CH₂CH₂COOH). ¹³C NMR (150.92 MHz, CDCl₃) δ 167.3, 137.6, 133.7, 129.0, 98.5, 70.36, 70.26, 70.21, 70.08, 69.9, 66.6, 58.1, 40.0. HRMS calcd for C₁₆H₂₃NO₆ [M + H]⁺, 452.0570; found, 452.0555.

1-(3-Iodophenyl)-1-oxo-5,8,11-trioxo-2-azatetradecan-14-oic acid (**22b**). 3-{2-[2-(2-Aminoethoxy)ethoxy]ethoxy}propanoic acid (120 mg 540 μ mol) and **9b** (620 mg 180 μ mol) were added to DMF (1.5 mL) in a 0.5–2 mL microwave vial. The solution was heated in a microwave at 120 °C for 8 min. Afterward water (5 mL) was added and the mixture was extracted with CH₂Cl₂ (3 \times 10 mL); the organic layers were combined and then extracted with water (5 \times 10 mL) and brine (10 mL) and dried over Na₂SO₄. The solvent was removed by rotary evaporation and the product was isolated as a white wax. Yield 34 mg, 42%; TLC (5% MeOH/CH₂Cl₂) R_f = 0.30. ¹H NMR (600.13 MHz, CDCl₃) δ 8.16 (dd, J = 1.5, 1.5 Hz, 1H, NHCOC₆HH₃I), 7.79–7.77 (m, 2H, NHCOC₆H₂H₂I), 7.24 (br s, NHCH₂CH₂O), 7.14 (dd, J = 7.8, 7.8 Hz, 1H, NHCOC₆HH₃I), 3.71 (t, J = 6.1 Hz, 2H,

NHCH₂CH₂O), 3.67–3.60 [m, 12H, (CH₂OCH₂)₃], 2.57 (t, J = 6.1 Hz, 2H, CH₂CH₂COOH). ¹³C NMR (151 MHz, CDCl₃) δ 175.5, 166.9, 140.8, 136.97, 136.82, 130.7, 127.0, 94.7, 71.08, 70.92, 70.80, 70.75, 70.4, 67.0, 40.6, 35.5. HRMS calcd for C₁₆H₂₃NO₆ [M + H]⁺, 452.0570; found, 452.0566.

(*S*)-20-[(*S*)-2-[(Benzyloxy)carbonyl]amino]-3-phenylpropanamido]-1-(4-iodophenyl)-1,14,21-trioxo-5,8,11-trioxo-2,15-diazadocosan-22-yl 2,4,6-Trimethylbenzoate (**23a**). To a solution of **22a** (36 mg, 80 μ mol) in anhydrous DMF (5 mL), PyBOP (42 mg, 80 μ mol) was added and dissolved at 0 °C under a stream of Ar. Et₃N (33 μ L, 240 μ mol) was added and the solution was left to stir for 5 min. Afterward, **6a** (56 mg, 80 μ mol) was added and the reaction mixture was stirred while warming to room temperature overnight. The solution was made up to 25 mL with water and extracted with CH₂Cl₂ (3 \times 10 mL), and the organic layers were combined and then extracted with water (5 \times 15 mL) and brine (5 \times 10 mL). The solvent was evaporated and the product was obtained as a white solid following flash chromatography (2–20% MeOH/CH₂Cl₂) as a white wax. Yield 18 mg, 22%; TLC (5% MeOH/CH₂Cl₂) R_f = 0.22; HPLC (method B) t_R = 16.7 min. ¹H NMR [600.13 MHz, (CD₃)₂SO] δ 8.58 (t, J = 5.6 Hz, 1H, CH₂NHCOAr), 8.50 (d, J = 7.4 Hz, 1H, NHCHCONH), 7.85 (d, J = 8.5 Hz, 2H, NHCOC₆H₂H₂I), 7.79 (t, J = 5.6 Hz, 1H, CH₂NHCOCH₂), 7.65–7.62 (m, 3H, NHCOC₆H₂H₂I and NHCHCOCH₂), 7.35–7.20 (m, 10H, Ph), 6.92 (s, 2H, Me₃C₆H₂CO), 4.98 (s, 2H, PhCH₂OCO), 4.92 (d, J = 17.2 Hz, 1H, COCHHO), 4.81 (d, J = 17.2 Hz, 1H, COCHHO), 4.37–4.32 (m, 2H, HNCHCO Phe and Lys), 3.57 (t, J = 6.5 Hz, 2H, COCH₂CH₂O), 3.53–3.39 (m, 12H, CH₂CH₂OCH₂CH₂OCH₂CH₂), 3.05–3.01 (m, 3H, CHCHHPh and CH₂NHCOCH₂), 2.82 (dd, J = 13.6, 9.7 Hz, 1H, CHCHHPh), 2.30 (m, 2H, COCH₂CH₂O), 2.28 [s, 6H, 2,6-(CH₃)₂C₆H₃CO], 2.26 [s, 3H, 4-(CH₃)₃C₆H₂CO], 1.83–1.77 (m, 1H, CHCHHCH₂CH₂), 1.61–1.53 (m, 1H, CHCHHCH₂CH₂), 1.41–1.24 (m, 4H, CHCH₂CH₂CH₂). ¹³C NMR (150.92 MHz; (CD₃)₂SO): δ 202.6, 172.0, 169.8, 168.2, 165.6, 155.8, 139.1, 137.8, 137.1, 136.9, 134.9, 133.8, 129.9, 129.2, 129.1, 128.3, 128.2, 128.1, 127.7, 127.5, 126.3, 98.8, 69.7, 69.6, 69.5, 68.8, 66.8, 66.6, 65.3, 56.0, 55.9, 40.1, 38.2, 37.2, 36.1, 29.1, 28.7, 22.3, 20.7, 19.3. HRMS calcd for C₅₀H₆₂N₄O₁₁I [M + H]⁺, 1021.3460; found, 1021.3456.

(*S*)-20-[(*S*)-2-[(Benzyloxy)carbonyl]amino]-3-phenylpropanamido]-1-(3-iodophenyl)-1,14,21-trioxo-5,8,11-trioxo-2,15-diazadocosan-22-yl 2,4,6-Trimethylbenzoate (**23b**). To a solution of **22b** (26 mg 57 μ mol) in anhydrous DMF (5 mL), PyBOP (30 mg, 57 μ mol) was added and dissolved at 0 °C under a stream of Ar. Et₃N (8 μ L, 57 μ mol) was added and the solution was left to stir for 5 min. Afterward, **6a** (40 mg, 57 μ mol) and Et₃N (16 μ L, 114 μ mol) were added, and the reaction mixture was stirred and allowed to warm to room temperature overnight. The solution was made up to 25 mL with water and extracted with CH₂Cl₂ (3 \times 10 mL); the organic layers were combined and then extracted with water (5 \times 15 mL) and brine (5 \times 10 mL). The solvent was evaporated and the product was obtained as a white solid following flash chromatography (5% MeOH/CH₂Cl₂). Yield 0.216 g, 37%; mp 79–86 °C; TLC (10% MeOH/CH₂Cl₂) R_f = 0.51; HPLC (method B) t_R = 16.7 min. ¹H NMR [600.13 MHz, (CD₃)₂SO] δ 8.61 (t, J = 5.5 Hz, 1H, CH₂NHCOAr), 8.50 (d, J = 7.4 Hz, 1H, NHCHCONH), 8.19 (m, 1H, NHCOC₆HH₃I), 7.89–7.87 (m, 1H, NHCOC₆HH₃I), 7.79 (t, J = 5.7 Hz, 1H, CH₂NHCOCH₂), 7.64 (d, J = 8.2 Hz, 1H, NHCHCOCH₂), 7.34–7.18 (m, 11H, Ph and NHCOC₆HH₃I), 6.92 (s, 2H, Me₃C₆H₂CO), 4.97 (d, J = 5.2 Hz, 2H, PhCH₂OCO), 4.91 (d, J = 17.2 Hz, 1H, COCHHO), 4.80 (d, J = 17.2 Hz, 1H, COCHHO), 4.36–4.33 (m, 2H, HNCHCO Phe and Lys), 3.57 (t, J = 6.5 Hz, 2H, COCH₂CH₂O), 3.53–3.38 (m, 12H, CH₂CH₂OCH₂CH₂OCH₂CH₂), 3.05–3.01 (m, 3H, CHCHHPh and CH₂NHCOCH₂), 2.82 (dd, J = 13.6, 9.7 Hz, 1H, CHCHHPh), 2.29 (d, J = 6.5 Hz, 1H, COCH₂CHHO), 2.27 [s, 6H, 2,6-(CH₃)₂C₆H₃CO], 2.25 [s, 3H, 4-(CH₃)₃C₆H₂CO], 1.82–1.78 (m, 1H, CHCHHCH₂CH₂), 1.60–1.53 (m, 1H, CHCHHCH₂CH₂), 1.40–1.24 (m, 4H, CHCH₂CH₂CH₂). ¹³C NMR [150.92 MHz, (CD₃)₂SO] δ 202.6, 172.0, 172.0, 169.8, 168.2, 155.8, 139.6, 139.1, 137.8, 136.9, 136.4, 135.6, 134.9, 130.5, 129.9, 129.2, 128.3, 128.2, 128.1, 127.7, 127.5, 126.6, 126.3, 94.6, 69.7,

69.7, 69.6, 69.5, 68.7, 66.8, 66.6, 65.3, 56.0, 55.9, 40.0, 38.2, 37.2, 36.1, 29.1, 28.7, 22.4, 20.7, 19.3. HRMS calcd for $C_{50}H_{62}N_4O_{11}I$ $[M + H]^+$, 1021.3460; found, 1021.3484.

tert-Butyl 3-(2-{2-[2-(4-Tributylstannyl-1H-1,2,3-triazol-1-yl)ethoxy]ethoxy]ethoxy]propanoate (26). Tributyl(ethynyl)stannane (0.432 g, 1.37 mmol) and **25** (0.308 g, 1.80 mmol) were combined in toluene (3 mL) and heated to reflux at 120 °C for overnight. The solvent was evaporated and the product was isolated as a colorless oil following flash chromatography (12–100% EtOAc/hexanes). Yield 0.468 g, 66%; TLC (1:1 EtOAc/Hex) R_f = 0.33. 1H NMR (600 MHz, $CDCl_3$): δ 7.60 (s, 1H, triazole-H), 4.57 (t, J = 5.3 Hz, 2H, NCH_2CH_2O), 3.87 (t, J = 5.3 Hz, 2H, NCH_2CH_2O), 3.70 (t, J = 6.6 Hz, 2H, $CH_2CH_2COO^tBu$), 3.59–3.58 [m, 8H, $(OCH_2CH_2)_2$], 2.49 (t, J = 6.7 Hz, 2H, $CH_2CH_2COO^tBu$), 1.58–1.52 [m, 6H, $Sn(CH_2CH_2CH_3)_3$], 1.44 [s, 9H, $(CH_3)_3COOC$], 1.32 [m, 6H, $Sn(CH_2CH_2CH_3)_3$], 1.12–1.09 [m, 6H, $Sn(CH_2CH_2CH_3)_3$], 0.88 [t, J = 7.3 Hz, 9H, $(CH_2CH_2CH_2CH_3)_3$]. ^{13}C NMR (150.92 MHz, $CDCl_3$) δ 171.2, 144.5, 131.3, 80.9, 70.96, 70.89, 70.73, 70.1, 67.3, 49.9, 36.6, 29.4, 28.4, 27.6, 10.2. HRMS calcd for $C_{27}H_{53}N_3O_5Sn$ $[M + H]^+$, 620.3091; found, 620.3077.

tert-Butyl 3-(2-{2-[2-(4-Iodo-1H-1,2,3-triazol-1-yl)ethoxy]ethoxy]ethoxy]propanoate (27). To a solution of **26** (0.303 g, 0.49 mmol) in THF (10 mL), iodine (0.137 g, 0.54 mmol) was added and left to stir for 2 h. The solution volume was made up to 25 mL with EtOAc and extracted with saturated $Na_2S_2O_3$ (3 \times 20 mL) and brine (20 mL) and dried over $MgSO_4$. The solvent was removed by rotary evaporation, and the product was isolated as a clear colorless oil following flash chromatography (12–100% EtOAc/hexanes). Yield 0.187 mg, 84%; TLC (1:1 EtOAc/Hex) R_f = 0.18. 1H NMR (600.13 MHz, $CDCl_3$) δ 7.90 (s, 1H, triazole-H), 4.57 (t, J = 4.9 Hz, 2H, NCH_2CH_2O), 3.85 (t, J = 4.9 Hz, 2H, NCH_2CH_2O), 3.72 (t, J = 6.5 Hz, 2H, $CH_2CH_2COO^tBu$), 3.62–3.60 [m, 8H, $(OCH_2CH_2)_2$], 2.50 (t, J = 6.5 Hz, 2H, $CH_2CH_2COO^tBu$), 1.44 [s, 9H, $(CH_3)_3COOC$]. ^{13}C NMR (150.92 MHz, $CDCl_3$) δ 171.2, 130.6, 87.2, 80.9, 70.91, 70.80, 70.79, 69.6, 67.3, 51.0, 36.6, 28.5. HRMS calcd for $C_{15}H_{27}N_3O_5I$ $[M + H]^+$, 456.0995; found, 456.0981.

3-(2-{2-[2-(4-Iodo-1H-1,2,3-triazol-1-yl)ethoxy]ethoxy]ethoxy]propanoic Acid (28). To a solution of **27** (0.150 g, 0.33 mmol) in CH_2Cl_2 (10 mL) was added TFA (5 mL) dropwise at 0 °C, and the reaction mixture was left to stir for 3 h. The solvent was coevaporated with Et_2O , giving the product as a clear colorless oil. Yield 0.161 g, >99%; TLC (5% MeOH/ CH_2Cl_2) R_f = 0.23. 1H NMR (600 MHz, $CDCl_3$) δ 11.02 (br s, CH_2COOH), 7.94 (s, 1H, triazole-H), 4.60 (t, J = 4.9 Hz, 2H, NCH_2CH_2O), 3.87 (t, J = 4.9 Hz, 2H, NCH_2CH_2O), 3.80 (t, J = 6.1 Hz, 2H, CH_2CH_2COOH), 3.68–3.67 (m, 2H, CH_2), 3.64–3.60 (m, 6H, CH_2), 2.67 (t, J = 6.1 Hz, 2H, CH_2CH_2COOH). ^{13}C NMR (150.92 MHz, $CDCl_3$) δ 176.4, 131.1, 86.0, 70.5, 70.4, 70.4, 70.3, 69.1, 66.4, 50.9, 34.8. HRMS calcd for $C_{11}H_{19}N_3O_5I$ $[M + H]^+$, 400.0370; found, 400.0368.

(S)-18-[(S)-2-[(Benzyloxy)carbonyl]amino]-3-phenylpropanamido]-1-(4-iodo-1H-1,2,3-triazol-1-yl)-12,19-dioxo-3,6,9-trioxa-13-azaicosan-20-yl 2,4,6-Trimethylbenzoate (29). To a solution of **28** (0.037 g, 0.091 mmol) in anhydrous DMF (10 mL), PyBOP (0.047 g, 0.091 mmol) was added and dissolved at 0 °C under a stream of Ar. Et_3N (0.020 mL, 0.182 mmol) was added and the solution was left to stir for 5 min. Afterward, **6a** (0.040 g, 0.057 mmol) was added and the reaction mixture was stirred and allowed to warm to room temperature overnight. The solution was made up to 25 mL with water and extracted with CH_2Cl_2 (3 \times 20 mL), and the combined organic layers were extracted with water (5 \times 10 mL) and brine (3 \times 20 mL). The solvent was evaporated and the product was obtained as a white solid following flash chromatography (1–20% MeOH/ CH_2Cl_2). Yield 0.22 g, 37%; mp 91–95 °C; TLC (10% MeOH/ CH_2Cl_2) R_f = 0.67; HPLC (method B) R_t = 17.1 min. 1H NMR [600.13 MHz, $(CD_3)_2SO$] δ 8.50 (d, J = 7.5 Hz, 1H, $NHCHCONH$), 7.79 (t, J = 5.6 Hz, 1H, $CH_2NHCOCH_2$), 7.64 (d, J = 8.2 Hz, 1H, $NHCHCOCH_2$), 7.34–7.18 (m, 10H, Ph), 6.91 (s, 2H, $Me_3C_6H_2CO$), 4.97 (s, 2H, $PhCH_2OCO$), 4.91 (d, J = 17.2 Hz, 1H, $COCHHO$), 4.80 (d, J = 17.2 Hz, 1H, $COCHHO$), 4.36–4.32 (m, 2H, $HNCHCO$ Phe and Lys), 3.63–3.56 (m, 4H, $COCH_2CH_2O$), 3.47 (m, 12H,

$CH_2CH_2OCH_2CH_2OCH_2CH_2$), 3.03–2.99 (m, 3H, $CHCHHPh$ and $CH_2NHCOCH_2$), 2.82–2.81 (m, 1H, $CHCHHPh$), 2.27 [s, 6H, 2,6- $(CH_3)_3C_6H_2CO$], 2.25 [s, 3H, 4- $(CH_3)_3C_6H_2CO$], 1.63–1.54 (m, 2H, $CHCH_2CH_2CH_2$), 1.40–1.32 (m, 4H, $CHCH_2CH_2CH_2$). ^{13}C NMR [150.92 MHz, $(CD_3)_2SO$] δ 202.8, 172.1, 169.9, 168.4, 156.0, 139.3, 137.9, 137.1, 135.1, 130.6, 130.1, 128.41, 128.37, 128.23, 128.14, 127.84, 127.66, 126.5, 88.5, 69.85, 69.80, 69.77, 69.71, 69.68, 69.65, 69.62, 67.0, 65.4, 56.20, 56.05, 38.3, 37.4, 36.3, 30.9, 29.2, 28.9, 20.8, 19.5. HRMS calcd for $C_{45}H_{58}N_6O_{10}I$ $[M + H]^+$, 969.3259; found, 969.3243.

6-[4-[Tris(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)stannyl]benzamido]hexanoic Acid (31). 1,3,5,7-Tetramethyl-6-(2,4-dimethoxyphenyl)-2,4,8-trioxa-6-phosphaadamantane (8.0 mg, 27 μ mol) and $Pd(OAc)_2$ (3.0 mg, 13 μ mol), each dissolved in degassed THF (1 mL), were added to a 2–5 mL microwave vial purged with Ar and mixed together for 15 min. Tris(1H,1H,2H,2H-perfluorooctyl)tin hydride (850 mg, 730 μ mol) dissolved in THF (1 mL) was added, and the solution was stirred for 15 min. A solution of **10a** (120 mg, 332 μ mol) dissolved in THF (1 mL) was then added, and the reaction mixture was heated by microwave irradiation at 85 °C for 30 min. The mixture was filtered through silica/KF (3:1) and then further purified by column chromatography [1–5% MeOH/ CH_2Cl_2 (with 1% AcOH)]. The desired fractions were then diluted with water and the product, a white wax, was obtained following rotary evaporation. Yield 117 mg, 35%; TLC (5% MeOH/ CH_2Cl_2) R_f = 0.57. 1H NMR (600.13 MHz, $CDCl_3$) 1H NMR (600 MHz, $CDCl_3$) δ 7.77 (d, J = 8.1 Hz, 2H, ArH), 7.51–7.42 (m, 2H, ArH), 6.25 (t, J = 5.8 Hz, 1H, $NHCH_2CH_2$), 3.48–3.45 (m, J = 6.6 Hz, 2H, $NHCH_2CH_2$), 2.37 (t, J = 7.3 Hz, 2H, CH_2CH_2COOH), 2.62–2.35 [m, 6H, $Sn(CH_2CH_2)_3$], 1.71–1.67 (m, 2H, CH_2CH_2COOH), 1.66–1.62 (m, 2H, $NHCH_2CH_2$), 1.48–1.42 (m, 2H, $CH_2CH_2CH_2COOH$), 1.38–1.33 [m, 6H, $Sn(CH_2CH_2)_3$]. ^{13}C NMR (150.92 MHz, $CDCl_3$) δ 167.6, 141.5, 136.4, 135.8, 127.1, 40.1, 33.9, 29.5, 27.8, 26.6, 24.5, –1.0. HRMS calcd for $C_{37}H_{29}NO_3F_{39}Sn$ $[M + H]^+$, 1396.0554; found, 1396.0468.

(S)-3-[(S)-2-[(Benzyloxy)carbonyl]amino]-3-phenylpropanamido]-2-oxo-7-[6-{4-[Tris(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)stannyl]phenyl]amino]hexanamido]heptyl 2,4,6-Trimethylbenzoate (32). To a solution of **31** (42 mg, 30 μ mol) in anhydrous DMF (5 mL) was added PyBOP (16 mg, 30 μ mol), and the solids were allowed to dissolve at 0 °C under a stream of Ar. Et_3N (4.0 μ L, 30 μ mol) was added and the solution was left to stir for 5 min. Afterward, **6a** (21 mg, 30 μ mol) and Et_3N (8 μ L, 60 μ mol) were added and the solution was stirred and allowed to warm to room temperature overnight. Water (20 mL) was added and the solution was extracted with CH_2Cl_2 (3 \times 10 mL); the combined organic layers were extracted with water (5 \times 10 mL) and brine (3 \times 10 mL) and then dried over Na_2SO_4 . The solvent was evaporated and the product was obtained as a white wax following semipreparative HPLC (method B). Yield 0.008 g, 14%; TLC (5% MeOH/ CH_2Cl_2) R_f = 0.36; HPLC (method B) R_t = 25.1 min. 1H NMR [500.13 MHz, $(CD_3)_2SO$] δ 8.48 (d, J = 7.3 Hz, 1H, $NHCHCONH$), 8.40 (t, J = 4.8 Hz, 1H, $CH_2NHCOAr$), 7.80 (d, J = 7.8 Hz, 2H, $COC_6H_2H_2Sn$), 7.70 (t, J = 5.4 Hz, 1H, $CH_2NHCOCH_2$), 7.63–7.59 (m, 3H, $NHCHCOCH_2$ and $COC_6H_2H_2Sn$), 7.33–7.18 (m, 10H, Ph), 6.90 (s, 2H, $Me_3C_6H_2CO$), 4.96 (d, J = 4.4 Hz, 2H, $PhCH_2OCO$), 4.90 (d, J = 17.5 Hz, 1H, $COCHHO$), 4.80 (d, J = 17.0 Hz, 1H, $COCHHO$), 4.35–4.32 (m, 2H, $HNCHCO$ Phe and Lys), 3.24–3.20 (m, 2H, $CH_2NHCOAr$), 3.04–2.99 (m, 3H, $CHCHHPh$ and $CH_2NHCOCH_2$), 2.83–2.79 (m, 1H, $CHCHHPh$), 2.47–2.36 [m, 6H, $Sn(CH_2CH_2)_2$], 2.26 [s, 6H, 2,6- $(CH_3)_3C_6H_2CO$], 2.24 [s, 3H, 4- $(CH_3)_3C_6H_2CO$], 2.04 (t, J = 7.3 Hz, 2H, $CH_2NHCOCH_2$), 1.82–1.75 (m, 1H, $CHCHHCH_2CH_2$), 1.57–1.46 (m, 4H, $CHCHHCH_2CH_2$ and $NHCOCH_2CH_2$), 1.39–1.21 [m, 11H, $CHCH_2CHHCH_2$, CH_2CH_2NHCO , and $Sn(CH_2CH_2)_3$]. HRMS calcd for $C_{71}H_{68}N_4O_8Sn$ $[M + H]^+$, 1965.3455; found, 1965.2988.

1-Oxo-1-[4-[Tris(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)stannyl]phenyl]-5,8,11-trioxa-2-azatetradecan-14-oic acid (33). 1,3,5,7-Tetramethyl-6-(2,4-dimethoxyphenyl)-2,4,8-trioxa-6-phosphaadamantane (4 mg, 15 μ mol) and $Pd(OAc)_2$ (2 mg, 7 μ mol), each

dissolved in degassed THF (1 mL), were added to a 2–5 mL microwave vial purged with Ar and mixed together for 15 min. Tris(1*H*,1*H*,2*H*,2*H*-perfluorooctyl)tin hydride (470 mg, 400 μ mol) dissolved in THF (1 mL) was added, and the solution was stirred for 15 min. A solution of **22a** (82 mg, 182 μ mol) dissolved in THF (1 mL) was then added, and the solution was heated by microwave irradiation at 80 °C for 20 min. The mixture was filtered through Celite and the product was isolated as a white wax following reverse-phase flash chromatography (30–100% CH₃CN/H₂O; 100% THF). Yield 0.095 g, 35%; TLC (5% MeOH/CH₂Cl₂) *R*_f = 0.58. ¹H NMR (600.13 MHz, CDCl₃) δ 7.79 (d, *J* = 8.1 Hz, 2H, ArH), 7.46 (d, *J* = 8.1 Hz, 2H, ArH), 6.91 (t, *J* = 0.5 Hz, 1H, NHCH₂CH₂O), 3.76–3.56 [m, 14H NHCH₂CH₂O and (CH₂OCH₂)₃], 2.55 (t, *J* = 6.4 Hz, 2H, CH₂CH₂COOH), 2.35–2.29 [m, 6H, Sn(CH₂CH₂)₃], 1.32 [t, *J* = 8.2 Hz, 6H, Sn(CH₂CH₂)₃]. HRMS calcd for C₄₉H₃₅NO₆F₃₉Sn [M + H]⁺, 1486.0873; found, 1486.0826.

(*S*)-20-[(*S*)-2-[(Benzyloxy)carbonyl]amino]-3-phenylpropanamido]-1,14,21-trioxo-1-[4-[tris(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)stannyl]phenyl]-5,8,11-trioxa-2,15-diazadocosan-22-yl 2,4,6-Trimethylbenzoate (**34**). To a solution of **33** (38 mg, 26 μ mol) in anhydrous DMF (5 mL) was added PyBOP (140 mg, 26 μ mol), and the solids were allowed to dissolve at 0 °C under a stream of Ar. Et₃N (7 μ L, 52 μ mol) was added and the solution was left to stir for 5 min. Afterward, **6a** (21 mg, 30 μ mol) and Et₃N (4 μ L, 26 μ mol) were added and the solution was stirred while warming to room temperature overnight. Water (20 mL) was added and the solution was extracted with CH₂Cl₂ (3 \times 10 mL); the combined organic layers were extracted with water (5 \times 10 mL) and brine (3 \times 10 mL) and then dried over Na₂SO₄. The solvent was evaporated and the product was obtained as a white wax following semipreparative HPLC (method B). Yield 6 mg, 12%; TLC (5% MeOH/CH₂Cl₂) *R*_f = 0.09; HPLC (method B) *R* = 25 min. ¹H NMR [600.13 MHz, (CD₃)₂SO] δ 8.51–8.47 (m, 2H, CH₂NHCOAr and NHCHCONH), 7.81 (d, *J* = 8.1 Hz, 2H, NHCOC₆H₄Sn), 7.77 (t, *J* = 5.6 Hz, 1H, CH₂NHCOCH₂), 7.62 (d, *J* = 8.2 Hz, 1H, NHCHCOCH₂), 7.60–7.55 (m, 2H, NHCOC₆H₄Sn), 7.32–7.18 (m, 10H, Ph), 6.89 (s, 2H, Me₃C₆H₂CO), 4.96 (s, 2H, PhCH₂OCO), 4.90 (d, *J* = 17.2 Hz, 1H, COCHHO), 4.79 (d, *J* = 17.3 Hz, 1H, COCHHO), 4.35–4.31 (m, 2H, HNCHCO Phe and Lys), 3.55 (t, *J* = 6.5 Hz, 2H, COCH₂CH₂O), 3.51–3.39 (m, 12H, CH₂CH₂OCH₂CH₂OCH₂CH₂), 3.04–3.00 (m, 3H, CHCHHPh and CH₂NHCOCH₂), 2.81 (dd, *J* = 13.6, 9.5 Hz, 1H, CHCHHPh), 2.46–2.37 [m, 6H, Sn(CH₂CH₂)₃], 2.28 (d, *J* = 6.5 Hz, 2H, COCH₂CH₂O), 2.24 [s, 6H, 2,6-(CH₃)₃C₆H₂CO], 2.23 [s, 3H, 4-(CH₃)₃C₆H₂CO], 1.80–1.77 (m, 1H, CHCHHCH₂CH₂), 1.59–1.52 (m, 1H, CHCHHCH₂CH₂), 1.38–1.22 [m, 10H, CHCH₂CH₂CH₂ and Sn(CH₂CH₂)₃]. HRMS calcd for C₇₄H₇₇F₃₉N₅O₁₁Sn [M + NH₄]⁺, 2072.4038; found, 2072.3989.

Screening Studies. Optimization of Enzyme Concentration. Cathepsin B (500 nM) was preincubated for 30 min at room temperature in a solution of 5 mM dithiothreitol (DTT) and 0.01% (v/v) Tween-20. Cathepsin B was added to the wells of a 96-well microplate containing the assay buffer [25 mM K₂PO₄, 1 mM ethylenediaminetetraacetic acid (EDTA), 250 mM NaCl, and 3% (v/v) DMSO, pH = 6.0], and Cbz-Arg-Arg-pNA (50 μ L) was added, resulting in enzyme concentrations from 1.25 to 25 nM and substrate concentration of 1 mM. Formation of the *p*-nitroanilide (pNA) product was monitored for 73 min at 405 nm at 37 °C. Measurements were obtained in triplicate. Initial rates (ν_0) were measured from the slope obtained during the first 10 min.

Determination of *K*_m. Cathepsin B (200 nM) was preincubated for 30 min at 37 °C in a solution of 5 mM DTT and 0.01% (v/v) Tween-20. Cathepsin B (5 μ L) was added to the wells of a 96-well microplate containing the assay buffer. Cbz-Arg-Arg-pNA (50 μ L) was then added, resulting in an enzyme concentration of 5 nM and substrate concentrations from 125 μ M to 3 mM. Formation of the pNA product was monitored for 15 min at 405 nm at 37 °C. Measurements were obtained in triplicate. Initial rates (ν_0) were measured from the slope obtained during the first 10 min. *K*_m was determined from $\nu_0 = V_{\max}[S]/(K_m + [S])$ and solved by use of GraphPad Prism software.

Determination of Inhibition Constants. Cathepsin B (200 nM) was preincubated for 30 min at 37 °C in a solution of 5 mM DTT and 0.01% (v/v) Tween-20. The substrate, Cbz-Arg-Arg-pNA (25 or 40 μ L), and the AOMKs (50 μ L) were added to the wells of a 96-well microplate containing the assay buffer. The reaction was initiated by addition of cathepsin B, resulting in substrate concentrations of 500 or 800 μ M, inhibitor concentrations from 25 nM to 1 μ M, and an enzyme concentration of 5 nM. Formation of the pNA product was monitored for 60 min at 405 nm at 37 °C. Measurements were obtained in triplicate. Absorbance versus time measurements were analyzed by nonlinear regression to determine the pseudo-first-order rate constant (*k*_{obs}) as Abs = Ae^{−*k*_{obs}*t*} + B. The second-order rate constant (*k*_i/*K*_i), the apparent inactivation rate (*k*_i), and the inhibition constant (*K*_i) (where possible) were determined from *k*_{obs} = *k*_i[I]/(*K*_i + [I]) for hyperbolic relationships or *k*_{obs} = (*k*_i/*K*_i)[I] for linear relationships. Equations were solved by use of GraphPad Prism software.

Radiochemical Methods. [¹²⁵I]-(*S*)-3-[(*S*)-2-[(Benzyloxy)carbonyl]amino]-3-phenylpropanamido]-7-[6-(4-iodobenzamido)hexanamido]-2-oxoheptyl 2,4,6-Trimethylbenzoate ([¹²⁵I]**11a**). To a tube containing iodogen (5 μ g, 0.01 μ mol) in EtOH (25 μ L) was added **32** (100 μ g, 0.05 μ mol) in EtOH (100 μ L). AcOH (5 μ L) and [¹²⁵I]NaI (18.5 MBq) in 0.1% NaOH (10 μ L) were added, and after 10 min the reaction was quenched with 0.1 M Na₂S₂O₅ (25 μ L). The reaction mixture was diluted with water (1.5 mL) and loaded onto a FSPE cartridge (1 g). The FSPE cartridge was preactivated by washing with dimethylformamide (1 mL) and water (6 mL). Unreacted [¹²⁵I]NaI was eluted with water (10 mL) and the pure product was eluted with 80% EtOH (10 mL), while the excess precursor remained on the cartridge. Radiochemical yield (RCY) = 32–36% (*n* = 3); specific activity >23.6 GBq/ μ mmol; HPLC *R* = 14.8 min; log *P* (pH 7.4) = 1.05 \pm 0.01.

[¹²⁵I]-(*S*)-20-[(*S*)-2-[(Benzyloxy)carbonyl]amino]-3-phenylpropanamido]-1-(4-iodophenyl)-1,14,21-trioxo-5,8,11-trioxa-2,15-diazadocosan-22-yl 2,4,6-Trimethylbenzoate ([¹²⁵I]**23a**). To a tube containing iodogen (2.5 μ g, 0.005 μ mol) in EtOH (25 μ L) was added **34** (100 μ g, 0.05 μ mol) in EtOH (100 μ L). AcOH (5 μ L) and [¹²⁵I]NaI (18.5 MBq) in 0.1% NaOH (10 μ L) were added, and after 10 min the reaction was quenched with 0.1 M Na₂S₂O₅ (25 μ L). The reaction mixture was diluted with water (1.5 mL) and loaded onto a FSPE cartridge (1 g). The FSPE cartridge was preactivated by washing with dimethylformamide (1 mL) and water (6 mL). Unreacted [¹²⁵I]NaI was eluted with water (10 mL) and the pure product was eluted with 50% EtOH (10 mL), while the excess precursor remained on the cartridge. RCY = 26–35% (*n* = 3); specific activity >23.1 GBq/ μ mmol; HPLC *R* = 14.1 min; log *P* (pH 7.4) = 0.95 \pm 0.01.

Determination of Log *P* (pH 7.4). A solution of [¹²⁵I]**23** or [¹²⁵I]**11** (444 kBq) in 10% EtOH in phosphate-buffered saline (PBS, 300 μ L) was added to a 1:1 mixture of *n*-octanol/PBS (pH 7.4) (2 mL); the mixture was vortexed for 20 min and centrifuged for 30 min at 6000 rpm. Aliquots (60 μ L) were removed from each layer in triplicate and added to preweighed tubes. The tubes were reweighed and the amount of radioactivity was measured on a γ counter. The partition coefficient, *P*, was calculated as *P* = activity concentration in *n*-octanol/activity concentration in aqueous buffer.

Labeling of Cathepsin B with ABPs. Human liver cathepsin B (1 μ g) was incubated in 1 \times binding buffer (5 mM Tris, pH = 5.5, 5 mM MgCl₂, and 2 mM DTT) containing RIPA buffer (100 mM Tris, pH = 8, 50 mM NaCl, 1% IGEPAL CA-630, 0.5% sodium deoxycholate, and 0.1% SDS) in the presence of either of CA-074 or DMSO for 1 h on ice. [¹²⁵I]**11a** or [¹²⁵I]**23a** (approximately 1 \times 10⁶ counts per minute, cpm) was added to each sample to give a total volume of 30 μ L, and the mixtures were incubated for 2 h at 0 °C. The assay was stopped by the addition of 6 \times sample buffer (9% SDS, 60% glycerol, 375 mM Tris, pH 6.8, 0.015% bromophenol blue, and 12% β -mercaptoethanol) to a final concentration of 1 \times and incubated at room temperature for 30 min. Following incubation, aliquots (30 μ L) of the mixtures were loaded onto a 10% Mini-Protean TGX precast gel and analyzed by SDS–PAGE. Gels were incubated overnight in gel-shrinking solution (65% methanol, 0.5% glycerol) while shaking at 4 °C. Gels were dried

for 2 h at room temperature by use of a commercial gel-drying kit and then exposed to a phosphor imaging screen for 72 h.

Animal Model. MDA-MB-231 cells were purchased from the American Type Culture Collection (ATCC) and cultured in accordance with supplier guidelines. Animal studies were approved by the Animal Research Ethics Board at McMaster University in accordance with Canadian Council on Animal Care (CCAC) guidelines. Female CD1 nu/nu mice (5–6 weeks old) were obtained from Charles River Laboratories (Senneville, QC) and were maintained under specific-pathogen-free (SPF) conditions with 12 h light/dark cycles and given food and water ad libitum. To create the tumor xenograft model, CD1 nu/nu female mice were injected with 2.0×10^6 MDA-MB-231 cells in 100 μ L of PBS/Matrigel (1:1; BD Biosciences, Mississauga, ON, and Invitrogen, Burlington, ON, respectively) subcutaneously into the right flank. Tumors were allowed to grow for approximately 2–3 weeks prior to biodistribution studies.

Biodistribution Studies. [125 I]11a. CD1 nu/nu mice ($n = 15$) were administered approximately 259 kBq of [125 I]11a (3.7 GBq/mL) in 10% EtOH in sterile PBS via tail vein injection. After 30 min, 5 h, and 23 h, groups of mice ($n = 5$) were anesthetized with 3% isoflurane and euthanized via exsanguination, and the indicated organs and tissues were collected by dissection and weighed. Activities were measured on a γ counter and reported as percent injected dose per gram (ID/g) of each organ, tissue, or fluid.

[125 I]23a. These studies were performed in a similar manner as for [125 I]11a, except CD1 nu/nu mice ($n = 9$) were administered approximately 74 kBq of [125 I]23a (3.7 GBq/mL).

■ ASSOCIATED CONTENT

■ Supporting Information

Four schemes depicting synthesis of 6a/6b, 30, 32, and 34; three figures showing optimization of enzyme concentration and determination of K_m , K_i , and k_i/K_i ; additional text with synthetic details; and 151 additional figures with ^1H NMR, ^{13}C NMR, and HRMS spectroscopic data for 1–34. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*Telephone 905-525-9140, ext 20182; fax 905-522-2509; e-mail valliant@mcmaster.ca.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank Professor Fred Capretta (McMaster University) for providing samples of the phosphadamantane ligand. Financial support for this research was provided by NSERC (Canada), Ontario Research Fund, the Canadian Institutes of Health Research, and the Ontario Institute for Cancer Research through funding provided by the Province of Ontario.

■ ABBREVIATIONS USED

AOMK, acyloxymethyl ketone; ABP, activity-based probe; Boc, *tert*-butoxycarbonyl; Cbz, carboxybenzyl; DMSO, dimethyl sulfoxide; DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; DTT, dithiothreitol; FSPE, fluorosolid-phase extraction; HPLC, high-pressure (performance) liquid chromatography; IBCF, isobutylchloroformate; ID/g, injected dose per gram; NIRF, near-infrared fluorescent/fluorescence; NMI, nuclear molecular imaging; NMM, *N*-methylmorpholine; PEG, poly(ethylene glycol); PET, positron emission tomography; pi, postinjection; pNA, *p*-nitroanilide; PyBOP, benzo-

triazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate; SDS–PAGE, sodium dodecyl sulfate–polyacrylamide gel electrophoresis; SPECT, single photon emission computed tomography; TFA, trifluoroacetic acid

■ REFERENCES

- (1) Powers, J. C.; Asgian, J. L.; James, K. E. Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases. *Chem. Rev.* **2002**, *102*, 4639–4750.
- (2) Jedeszko, C.; Sloane, B. F. Cysteine Cathepsins in Human Cancer. *Biol. Chem.* **2004**, *385*, 1017–1027.
- (3) Sloane, B. F.; Moin, K.; Krepela, E.; Rozhin, J. Cathepsin B and Its Endogenous Inhibitors: The Role in Tumor Malignancy. *Cancer Metastasis Rev.* **1990**, *9*, 333–352.
- (4) Sloane, B. F.; Yan, S.; Podgorski, I.; Linebaugh, B. E.; Cher, M. L.; Mai, J.; Cavallo-Medved, D.; Sameni, M.; Dosesescu, J.; Moin, K. Cathepsin B and Tumor Proteolysis: Contribution of the Tumor Microenvironment. *Semin. Cancer Biol.* **2005**, *15*, 149–157.
- (5) Roshly, S.; Sloane, B. F.; Moin, K. Pericellular Cathepsin B and Malignant Progression. *Cancer Metastasis Rev.* **2003**, *22*, 271–286.
- (6) Qian, F.; Bajkowski, A. S.; Steiner, D. F.; Chan, S. J.; Frankfater, A. Expression of Five Cathepsins in Murine Melanomas of Varying Metastatic Potential. *Cancer Res.* **1989**, *49*, 4870–4875.
- (7) Sloane, B.; Honn, K.; Sadler, J.; Turner, W.; Kimpson, J.; Taylor, J. D. Cathepsin B Activity in B16 Melanoma Cells: A Possible Marker for Metastatic Potential. *Cancer Res.* **1981**, *42*, 980–986.
- (8) Sloane, B. F.; Dunn, J. R.; Honn, K. V. Lysosomal Cathepsin B: Correlation with Metastatic Potential. *Science* **1981**, *212*, 1151–1153.
- (9) Recklies, A. D.; Tiltman, K. J.; Stoker, T. A. M. Secretion of Proteinases from Malignant and Nonmalignant Human Breast Tissue. *Cancer Res.* **1980**, *40*, 550–556.
- (10) Joyce, J. A.; Baruch, A.; Chehade, K.; Meyer-Morse, N.; Giraudo, E.; Tsai, F.-Y.; Greenbaum, D. C.; Hager, J. H.; Bogoy, M.; Hanahan, D. Cathepsin Cysteine Proteases Are Effectors of Invasive Growth and Angiogenesis during Multistage Tumorigenesis. *Cancer Cell* **2004**, *5*, 443–453.
- (11) Cavallo-Medved, D.; Rudy, D.; Blum, G.; Bogoy, M.; Caglic, D.; Sloane, B. F. Live-Cell Imaging Demonstrates Extracellular Matrix Degradation in Association with Active Cathepsin B in Caveolae of Endothelial Cells during Tube Formation. *Exp. Cell. Res.* **2009**, *315*, 1234–1246.
- (12) Kisin-Finifer, E.; Ferber, S.; Blau, R.; Satchi-Fainaro, R.; Shabat, D. Synthesis and Evaluation of New NIR-Fluorescent Probes for Cathepsin B: ICT versus FRET as a Turn-ON Mode-of-Action. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 2453–2458.
- (13) Weissleder, R.; Tung, C.-H.; Mahmood, U.; Bogdanov, A. J. In Vivo Imaging of Tumors with Protease Activated Near-Infrared Fluorescent Probes. *Nat. Biotechnol.* **1999**, *17*, 375–378.
- (14) Blum, G.; von Degenfeld, G.; Merchant, M. J.; Blau, H. M.; Bogoy, M. Noninvasive Optical Imaging of Cysteine Protease Activity Using Fluorescently Quenched Activity-Based Probes. *Nat. Chem. Biol.* **2007**, *3*, 668–677.
- (15) Verdoes, M.; Oresic Bender, K.; Segal, E.; van der Linden, W. A.; Syed, S.; Withana, N. P.; Sanman, L. E.; Bogoy, M. Improved Quenched Fluorescent Probe for Imaging of Cysteine Cathepsin Activity. *J. Am. Chem. Soc.* **2013**, *135*, 14726–14730.
- (16) Mahmood, U.; Tung, C. H.; Bogdanov, A.; Weissleder, R. Near-Infrared Optical Imaging of Protease Activity for Tumor Detection. *Radiology* **1999**, *213*, 866–870.
- (17) Bogdanov, A. A., Jr.; Lin, C. P.; Simonova, M.; Matuszewski, L.; Weissleder, R. Cellular Activation of the Self-Quenched Fluorescent Reporter Probe in Tumor Microenvironment. *Neoplasia* **2002**, *4*, 228–236.
- (18) Ntziachristos, V.; Bremer, C.; Graves, E. E.; Ripoll, J.; Weissleder, R. In Vivo Tomographic Imaging of Near-Infrared Fluorescent Probes. *Mol. Imaging* **2002**, *1*, 82–88.
- (19) Marten, K.; Bremer, C.; Khazaie, K.; Sameni, M.; Sloane, B.; Tung, C.; Weissleder, R. Detection of Dysplastic Intestinal Adenomas

Using Enzyme-Sensing Molecular Beacons in Mice. *Gastroenterology* **2002**, *122*, 406–414.

(20) Tian, X.; Baek, K.-H.; Shin, I. Dual-Targeting Delivery System for Selective Cancer Cell Death and Imaging. *Chem. Sci.* **2013**, *4*, 947.

(21) Chowdhury, M. A.; Moya, I. A.; Bhilocha, S.; McMillan, C. C.; Vigliarolo, B. G.; Zehbe, I.; Phenix, C. P. Prodrug-Inspired Probes Selective to Cathepsin B over Other Cysteine Cathepsins. *J. Med. Chem.* **2014**, *57*, 6092–6104.

(22) Paulick, M. G.; Bogoy, M. Development of Activity-Based Probes for Cathepsin X. *ACS Chem. Biol.* **2011**, *6*, 563–572.

(23) Blum, G.; Mullins, S. R.; Keren, K.; Fonovic, M.; Jedszko, C.; Rice, M. J.; Sloane, B. F.; Bogoy, M. Dynamic Imaging of Protease Activity with Fluorescently Quenched Activity-Based Probes. *Nat. Chem. Biol.* **2005**, *1*, 203–209.

(24) Pratt, M. R.; Sekedat, M. D.; Chiang, K. P.; Muir, T. W. Direct Measurement of Cathepsin B Activity in the Cytosol of Apoptotic Cells by an Activity-Based Probe. *Chem. Biol.* **2009**, *16*, 1001–1012.

(25) Hang, H. C.; Loureiro, J.; Spooner, E.; van der Velden, A. W. M.; Kim, Y.; Pollington, A. M.; Maehr, R.; Starnbach, M. N.; Ploegh, H. L. Mechanism-Based Probe for the Analysis of Cathepsin Cysteine Proteases in Living Cells. *ACS Chem. Biol.* **2006**, *1*, 713–723.

(26) Smith, R. A.; Copp, L. J.; Coles, P. J.; Pauls, H. W.; Robinson, V. J.; Spencer, R. W.; Heard, S. B.; Krantz, A. New Inhibitors of Cysteine Proteinases: Peptidyl Acyloxymethyl Ketones and the Quiescent Nucleofuge Strategy. *J. Am. Chem. Soc.* **1988**, *110*, 4429–4431.

(27) Krantz, A.; Copp, L. J.; Coles, P. J.; Smith, R. A.; Heard, S. B. Peptidyl (Acyloxy)methyl Ketones and the Quiescent Affinity Label Concept: The Departing Group as a Variable Structural Element in the Design of Inactivators of Cysteine Proteinases. *Biochemistry* **1991**, *46*, 4678–4687.

(28) Wagner, B. M.; Smith, R. A.; Coles, P. J.; Copp, L. J.; Ernest, M. J.; Krantz, A. In Vivo Inhibition of Cathepsin B by Peptidyl (Acyloxy)methyl Ketones. *J. Med. Chem.* **1994**, *37*, 1833–1840.

(29) Kato, D.; Boatright, K. M.; Berger, A. B.; Nazif, T.; Blum, G.; Ryan, C.; Chehade, K. A. H.; Salvesen, G. S.; Bogoy, M. Activity-Based Probes That Target Diverse Cysteine Protease Families. *Nat. Chem. Biol.* **2005**, *1*, 33–38.

(30) Edgington, L. E.; Verdoes, M.; Bogoy, M. Functional Imaging of Proteases: Recent Advances in the Design and Application of Substrate-Based and Activity-Based Probes. *Curr. Opin. Chem. Biol.* **2011**, *15*, 798–805.

(31) Lee, M.; Fridman, R.; Mobashery, S. Extracellular Proteases as Targets for Treatment of Cancer Metastases. *Chem. Soc. Rev.* **2004**, *33*, 401–409.

(32) Ren, G.; Blum, G.; Verdoes, M.; Liu, H.; Syed, S.; Edgington, L. E.; Gheysens, O.; Miao, Z.; Jiang, H.; Gambhir, S. S.; Bogoy, M.; Cheng, Z. Non-Invasive Imaging of Cysteine Cathepsin Activity in Solid Tumors Using a ^{64}Cu -Labeled Activity-Based Probe. *PLoS One* **2011**, *6*, No. e28029.

(33) Shokeen, M.; Anderson, C. J. Molecular Imaging of Cancer with Copper-64 Radiopharmaceuticals and Positron Emission Tomography (PET). *Acc. Chem. Res.* **2009**, *42*, 832–841.

(34) Maresca, K. P.; Hillier, S. M.; Femia, F. J.; Keith, D.; Barone, C.; Joyal, J. L.; Kozikowski, A. P.; Barrett, J. A.; Eckelman, W. C.; Babich, J. W.; Zimmerman, C. N. A Series of Halogenated Heterodimeric Inhibitors of Prostate Specific Membrane Antigen (PSMA) as Radiolabeled Probes for Targeting Prostate Cancer. *J. Med. Chem.* **2009**, *52*, 347–357.

(35) Chen, Y.; Foss, C. A.; Byun, Y.; Nimmagadda, S.; Pullambhatla, M.; Fox, J. J.; Castaneres, M.; Lupold, S. E.; Babich, J. W.; Mease, R. C.; Pomper, M. G. Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer. *J. Med. Chem.* **2008**, *51*, 7933–7943.

(36) Wieland, D. M.; Wu, J.; Brown, L. E.; Mangner, T. J.; Swanson, D. P.; Beierwaltes, W. H. Radiolabeled Adrenergic Neuron-Blocking Agents: Adrenomedullary Imaging with [^{131}I]Iodobenzylguanidine. *J. Nucl. Med.* **1980**, *21*, 349–353.

(37) Wafelman, A. R.; Konings, M. C. P.; Hoefnagel, C. A.; Maes, R. A. A.; Beijnen, J. H. Synthesis, Radiolabelling and Stability of

Radioiodinated M-Iodobenzylguanidine, a Review. *Appl. Radiat. Isot.* **1994**, *45*, 997–1007.

(38) Michelot, J. M.; Moreau, M. F.; Labarre, P. G.; Madelmont, J. C.; Veyre, A. J.; Papon, J. M.; Parry, D. F.; Bonafous, J. F.; Boire, J. Y.; Desplanches, G. G. Synthesis and Evaluation of New Iodine-125 Radiopharmaceuticals as Potential Tracers for Malignant Melanoma. *J. Nucl. Med.* **1991**, *32*, 1573–1580.

(39) Spezzacatena, C.; Pepe, A.; Green, L. M.; Sandberg, L. B.; Bochicchio, B.; Tamburro, A. M. Synthesis, Solution Structure and Biological Activity of Val-Val-Pro-Gln, a Bioactive Elastin Peptide. *Eur. J. Org. Chem.* **2005**, 1644–1651.

(40) Katritzky, A. R.; Meher, G.; Angrish, P. Peptides by Extension at the N- or C-Termini of Lysine. *Chem. Biol. Drug. Des.* **2006**, *68*, 326–333.

(41) Katritzky, A. R.; Suzuki, K.; Singh, S. K. Highly Diastereoselective Peptide Chain Extensions of Unprotected Amino Acids with N-(Z-Aminoacyl)benzotriazoles. *Synthesis* **2004**, 2645–2652.

(42) Clark, J. H.; Miller, J. M. Hydrogen Bonding In Organic Synthesis V: Potassium Fluoride in Carboxylic Acids as an Alternative to Crown Ether with Acid Salts in the Preparation of Phenacyl Esters. *Tetrahedron Lett.* **1977**, 599–602.

(43) Musil, D.; Zucic, D.; Turk, D.; Engh, R. A.; Mayr, I.; Huber, R.; Popovic, T.; Turk, V.; Towatari, T.; Katunuma, N. The Refined 2.15 Å X-Ray Crystal Structure of Human Liver Cathepsin B: The Structural Basis for Its Specificity. *EMBO J.* **1991**, *10*, 2321–2330.

(44) Darwish, A.; Blacker, M.; Janzen, N.; Rathmann, S. M.; Czorny, S.; Hillier, S. M.; Joyal, J. L.; Babich, J. W.; Valliant, J. F. Triazole Appending Agent (TAAG): A New Synthon for Preparing Iodine-Based Molecular Imaging and Radiotherapy Agents. *ACS Med. Chem. Lett.* **2012**, *3*, 313–316.

(45) Ito, S.; Satoh, A.; Nagatomi, Y.; Hirata, Y.; Suzuki, G.; Kimura, T.; Satow, A.; Maehara, S.; Hikichi, H.; Hata, M.; Kawamoto, H.; Ohta, H. Discovery and Biological Profile of 4-(1-Aryltriazol-4-yl)-Tetrahydropyridines as an Orally Active New Class of Metabotropic Glutamate Receptor 1 Antagonist. *Bioorg. Med. Chem.* **2008**, *16*, 9817–9829.

(46) Moin, K.; Day, N. A.; Sameni, M.; Hasnain, S.; Hirammat, T.; Sloane, B. F. Human Tumour Cathepsin B Comparison with Normal Liver Cathepsin B. *Biochem. J.* **1992**, *285*, 427–434.

(47) Hasnain, S.; Hirammat, T.; Tam, A.; Mort, J. S. Characterization of Recombinant Rat Cathepsin B and Nonglycosylated Mutants Expressed in Yeast. *J. Biol. Chem.* **1992**, *267*, 4713–4721.

(48) Blum, G.; Weimer, R. M.; Edgington, L. E.; Adams, W.; Bogoy, M. Comparative Assessment of Substrates and Activity Based Probes as Tools for Non-Invasive Optical Imaging of Cysteine Protease Activity. *PLoS One* **2009**, *4*, No. e6374.

(49) Cutter, J. L.; Cohen, N. T.; Wang, J.; Sloan, A. E.; Cohen, A. R.; Panneerselvam, A.; Schluchter, M.; Blum, G.; Bogoy, M.; Basilion, J. P. Topical Application of Activity-Based Probes for Visualization of Brain Tumor Tissue. *PLoS One* **2012**, *7*, No. e33060.

(50) Donovan, A.; Forbes, J.; Dorff, P.; Schaffer, P.; Babich, J.; Valliant, J. F. A New Strategy for Preparing Molecular Imaging and Therapy Agents Using Fluorine-Rich (Fluorous) Soluble Supports. *J. Am. Chem. Soc.* **2006**, *128*, 3536–3537.

(51) Donovan, A. C.; Valliant, J. F. Fluorous Isocyanates: Convenient Synthons for the Preparation of Radioiodinated Compounds in High Effective Specific Activity. *J. Org. Chem.* **2009**, *74*, 8133–8138.

(52) McIntee, J. W.; Sundararajan, C.; Donovan, A. C.; Kovacs, M. S.; Capretta, A.; Valliant, J. F. A Convenient Method for the Preparation of Fluorous Tin Derivatives for the Fluorous Labeling Strategy. *J. Org. Chem.* **2008**, *73*, 8236–8243.

(53) Towatari, T.; Nikawa, T.; Murata, M.; Yokoo, C.; Tamai, M.; Hanada, K.; Katunuma, N. Novel Epoxysuccinyl Peptides: A Selective Inhibitor of Cathepsin B, in Vivo. *FEBS Lett.* **1991**, *280*, 311–315.

(54) Zajc, I.; Frangež, L.; Lah, T. T. Expression of Cathepsin B Is Related to Tumorigenicity of Breast Cancer Cell Lines. *Radiol. Oncol.* **2003**, *37*, 233–240.

(55) Wilbur, D. S.; Hadley, S. W.; Hylarides, M. D.; Abrams, P. G.; Beaumier, P. A.; Morgan, A. C.; Reno, J. M.; Fritzberg, A. R.

Development of a Stable Radioiodinating Reagent to Label Monoclonal Antibodies for Radiotherapy of Cancer. *J. Nucl. Med.* **1989**, 30, 216–226.